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Background: Recent studies have associated neck circumference (NC) with metabolic 
and cardiovascular disease risk factors. No studies designed to examine NC as a measure 
of cardiometabolic risks have been performed in Saudi Arabia (KSA).   
Objective: This study aimed to analyze the association between NC and several 
cardiometabolic risk factors, and to determine the cut-off point value of NC for predicting 
women at increased risk of metabolic syndrome (MetS). 
Methods: This cross-sectional study comprised of 700 participants (623 women and 77 
men aged 18–70). Study performed in Riyadh city, KSA. International Diabetes 
Federation (IDF) guidelines were used to diagnose MetS among the subjects. The main 
indicators studied were NC, waist circumference (WC), body mass index (BMI), body fat 
%, blood pressure, plasma glucose, total cholesterol, lipoproteins, triglycerides, and 
homeostasis model assessment-estimated insulin resistance (HOMA-IR) levels. 
!!
Covariance, and logistic regression analyses were used to evaluate the association of NC 
to cardiometabolic risk factors separately by genders. Receivers operating characteristic 
(ROC) curves analyses were used to determine the optimal cutoffs. 
Results: NC is associated with BMI and WC in men and women. In women, it is 
associated with cardiometabolic risk factors beyond other anthropometric indices. NC is 
independently associated with all cardiometabolic risk factors except LDL (P < 0.001). 
Fully adjusted OR (95% CI) values for incremental increases in NC for women were 1.70 
(1.48–2.94) for raised fasting glucose; 1.29 (1.15–1.45) for raised blood pressure; 1.25 
(1.13–1.38) for high triglycerides; 1.20 (1.02–1.40) for insulin resistance; and 1.14 (1.02–
1.40) for low HDLc. Women in the largest NC quartile were 13 times more likely [OR 
(95% CI): 13.39 (6.35 - 28.23)] to have MetS compared to the lowest NC quartile after 
adjustments for possible confounders (all P < 0.01). Finally, our results indicated that the 
appropriate NC to predict three or more metabolic risk factors in Saudi women is 35.5 
cm. This cutoff value was associated with a much greater risk of MetS in participants 
with both high and normal BMI and WC values. 
Conclusion: NC is significantly and independently associated with cardiometabolic risk 
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Chapter 1: Introduction  
The Kingdom of Saudi Arabia has undergone a remarkable and rapid economic 
development over the past two decades (1, 2). The discovery of oil in huge quantities 
generated sudden wealth, and the average family income increased sharply. The increase 
in income was found to be accompanied by a rise in cardiometabolic diseases, which 
were previously reported to be associated with the more economically developed 
countries. Of these, overweight and obesity are the most prominent and influential due to 
increased risk of morbidity and mortality. Obesity accounts for over 600 million deaths 
every year (3). The prevalence of overweight and obesity is rising to epidemic 
proportions at an alarming rate in both developed “Westernized” and developing 
countries around the world (4, 5, 6). Obesity will probably trade cigarette smoking as the 
main killer of Americans in the next century (7). The prevalence of obesity has increased 
by about 10-40% in the majority of European countries in the last ten years (8). Over the 
same period, the prevalence of obesity in the Gulf region found to be among the highest 
in the world (9). The prevalence of overweight and obesity among Saudi nation found to 
be around 55% (10).  Obesity-related diseases include type 2 diabetes, heart disease, 
stroke, and certain types of cancer, some of the leading causes of preventable death.  
Obesity epidemiology is the impetus for proper obesity care and appropriate 
allocation of resources for its control (11). Considering the great economic and human 
costs associated with obesity, prevention of this disease is an urgent need. Management 
of obesity is identical with prevention of cardiometabolic disease, and must be a priority. 
For intervention, prevention is vital to protect the long-term health of patients (12). There 
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are several methods of assessing overweight and obesity, such as bioelectrical 
impedance, dual-energy x-ray absorptiometry, and total body water, which are used for 
measuring body fat (13). Some methods are more applicable to primary clinics, such as 
height, weight, waist and hip circumferences are used for measuring body mass index 
(BMI), and waist/hip ratio (WHR). The most widely used assessment is the BMI. The 
BMI is a mathematical calculation used for determining the whole body adiposity, and is 
calculated by dividing a person's body weight in kilograms by the square of height in 
meters (14). BMI is not a sensitive indicator of either the amount or the distribution of 
body fat (15). Body fat distribution is verified through numerous methods, as waist 
circumference (WC), waist/hip ratio (WHR), and neck circumference (NC). WC is 
corresponded to abdominal visceral fat (VF), which is shown to have a major role in 
cardiometabolic risk (16, 17). On the other hand, upper body subcutaneous fat (SF) 
relates to cardiometabolic risk as much as abdominal VF (18).  Besides, the free fatty acid 
release from upper body subcutaneous fat was found to be larger than that from lower 
body subcutaneous fat (19), a further fact that strengthens the significance of measuring 
upper-body subcutaneous adipose tissue depots. The neck circumference is an index of 
upper body SF that correlates with whole body adiposity (BMI) (20), abdominal 
adiposity (WC and waist-to-hip ratio) (21), abdominal VF (18) and components of the 
metabolic syndrome (MetS), such as systolic and diastolic blood pressures, triglycerides, 
total cholesterol, fasting glucose and insulin resistance (IR) (22, 23, 24). Despite the 
popular use of the WC in the evaluation of cardiometabolic risk, it has some limitations 
(25).  Whereas, different clinical studies have been using different anatomical sites in 
measuring WC. However, specific site used to measure the WC influences the absolute 
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WC value that is obtained (26).  In addition, WC is subject to variations during the day 
and under health conditions (e.g. severe obesity, lipoabdominoplasty, Ascites). Finally, it 
might not be practical for large population studies or primary care clinics, especially in 
cold weather and heavy clothing. Measuring the neck circumference is easier than 
measuring the WC, which reveals a large variability in its procedure. Furthermore, the 
neck circumference measurements can be useful in clinical screenings for persons with an 
increased risk of cardiometabolic diseases (27).  
This is the first study that aids in establishment of neck circumference 
measurement as an accurate assessment tool for overweight and obesity for Saudi 
population. The main goals are to examine whether neck circumference can be used to 
identify overweight, obesity and to test its application in predicting the cardiometabolic 
risk factors in Saudi adult population in the city of Riyadh. The data generated will 
provide standardized assessment tools to determine accurate prevalence, treatment 
protocols, and achieve control of obesity among Saudi population. Moreover, findings 
will contribute in preventing the epidemic of obesity and its complications in Saudi 





1) To evaluate the ability of neck circumference in diagnosing overweight and 
obesity in study subjects or (adults). 
2) To specify the cardiometabolic risk factors that correlate with neck circumference; 
and examine whether neck circumference is associated with these cardiometabolic 
risk factors independently. 
3) To determine the optimal cutoff point value of neck circumference for predicting 
women at increased risk of metabolic syndrome. 
Research Questions  
Question 1: What is the association between overall obesity (as measured by BMI) and 
upper-body adiposity (as measured by nick circumference or by waist circumference) in 
Saudi adult?  
Question 2: What is the ability of neck circumference in predicting overweight and 
obesity in patients? 
Question 3: What are the cardiometabolic risk factors (central obesity, 
hypertriglyceridemia, reduced high density lipoprotein cholesterol (HDLc), elevated low 
density lipoprotein cholesterol (LDLc), hyperglycemia, hypertension, and insulin 
resistance (IR)) that correlate most closely with elevated neck circumference? 
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Question 4: What are the cardiometabolic risk factors central obesity, 
hypertriglyceridemia, reduced HDLc, elevated LDLc, hyperglycemia, hypertension and 
metabolic syndrome, and IR) that correlate most closely with elevated WC? 
Question 5:  Is neck circumference associated with these cardiometabolic risk factors 
independently? 
Question 6: What are the odds ratios for the development of the cardiometabolic risk 
factors (central obesity, hypertriglyceridemia, low HDLc, IR, hyperglycemia, 
hypertension and metabolic syndrome) in subjects with elevated neck circumference? 
Question 7: What are the optimal gender specific BMI cutoff values for the diagnosis of 
adiposity in Saudi adults that predict increased risk of the cardiometabolic risk factors? 
Question 8: What are the optimal gender specific WC cutoff values for the diagnosis of 
adiposity in Saudi adults that predict increased risk of the cardiometabolic risk factors? 
Question 9: What are the optimal gender specific neck circumference cutoff values for 
the diagnosis of adiposity in Saudi adults that predict increased risk of the 
cardiometabolic risk factors? 
Question 10: What is the prevalence of Saudi adults at risk of cardiometabolic factors 
using BMI (≥30kg/m2), WC (male > 94cm, and female > 80cm), and neck circumference 
determined in question 9?  
Question 11: Is there a synergistic effect for the joint levels of neck circumference and 
BMI or WC on the metabolic syndrome? 
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Literature Review  
Cardiometabolic risks or diseases  
Obesity 
Obesity is defined medically as a state of increased adipose tissue of sufficient 
magnitude to produce adverse health consequences and is associated with increased 
morbidity and mortality (28, 29). The main risk factors that lead to obesity, poor nutrition 
and inactivity combined, are the second leading cause of preventable death after tobacco. 
The morbidity and mortality risk from being overweight is proportional to its degree. 
Obesity is associated with significant increases in risk for Type2 diabetes mellitus, 
hyperlipidemia, high cholesterol, coronary artery disease, gallbladder disease, 
osteoarthritis, and degenerative joint disease. Colon, rectum and prostate cancer are more 
prevalent in obese men.  Whereas, in women, uterus, biliary tract, breast and ovary 
cancer are highly prevalent (30). 
 Obesity is a disease that affects nearly one-third of the American adult population 
(34.9% or approximately 79 million). The number of overweight and obese Americans 
has continued to increase since 1960, a trend that is not slowing down. Today, 78.6 
percent of adult Americans are categorized as being overweight or obese. Each year, 
obesity causes at least 300,000 excess deaths in the U.S., and healthcare costs of 
American adults with obesity amount to approximately $147 billion (American Obesity 




Hypertension is a medical condition in which the blood pressure is chronically 
elevated. Blood pressure is the force of blood pressing against the walls of the arteries. 
High blood pressure raises the heart's workload and can cause serious damage to the 
arteries. Persistent hypertension is one of the risk factors for strokes, heart attacks, heart 
failure and can cause chronic renal failure. Hypertension is classified as essential  
(primary) or secondary. In essential hypertension, no specific medical cause can explain a 
patient's condition. It may be due to family history or lifestyle. Most people with elevated 
blood pressure have essential hypertension. Secondary hypertension, on the other hand, is 
less common and is the result of using certain medicines or presence of another 
condition, such as kidney disease or adrenal gland tumor (32, 33). Elevated blood 
pressure is associated with obesity and glucose intolerance and insulin resistance. The 
strength of this relation varies in different populations (34, 35).  Globally, high blood 
pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths 
(36). 
Diabetes mellitus (DM)  
Diabetes mellitus is a metabolic disorder of impaired carbohydrate, fat, and 
protein metabolism either by lack of insulin secretion (Type1 diabetes) or by decrease in 
sensitivity of tissues to insulin (Type2 diabetes), or both (37). Diabetes mellitus 
characterized by hyperglycemia. Hyperglycemia is defined as impaired fasting glucose 
IFG (as defined by the American Diabetes Association), impaired glucose tolerance IGT 
or diabetes (38).  
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Diabetes was estimated to affect 415 million adults (20–79 years of age) 
worldwide in 2015. According to International Diabetes Federation (IDF), the number of 
people with diabetes in the world will reach 642 million by 2040 (39). More than 90% of 
diabetes cases are Type2 diabetes, a progressive disease that leads to dysfunction and 
failure of various organs and the emergence of retinopathy, neuropathy, and nephropathy 
(40). Type 2 diabetes increases the risk of heart disease, stroke, and all-cause mortality by 
1.4–4.5 times (41, 42). 
Dyslipidemia 
The dyslipidemia is a condition marked by abnormality in lipid or lipoprotein 
concentrations in the blood. A typical feature of obesity, insulin resistance, Type2 
diabetes, and metabolic syndrome, atherogenic dyslipidemia has emerged as an important 
risk factor for cardiovascular disease (CVD) and stroke. It characterized by increased 
total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein B, and 
triglyceride, and decrease high-density lipoprotein (HDL) cholesterol concentration in the 
blood. The lipid abnormalities are due to the interaction of genetic factors with 
environmental influences including diet, physical activity and stress (43, 44, 45). 
Dyslipidemia in obesity or metabolic syndrome are related to insulin resistance and some 





Insulin resistance (IR) 
Insulin resistance is the condition in which liver, skeletal muscle and adipose 
tissue cells become less sensitive and eventually resistant to insulin. Insulin resistance in 
fat cells results in suppressing lipogenesis while promotes lipolysis of stored triglycerides 
and hence increases of free fatty acids in the blood. In muscle, insulin resistance reduces 
whole body glucose uptake by 60-70% whereas in liver it reduces glucose storage, both 
would cause an increase in blood glucose (48, 49). Insulin resistance is present in most 
obese people. The insulin resistance seen in obesity is believed to involve primarily 
muscle and liver. Several studies have shown that upper body adiposity is strongly 
associated with insulin resistance. Excess upper body fat can be accumulated as 
subcutaneous (truncal) or intraperitoneal (visceral) fat. Results from numerous studies 
suggest that excess visceral fat is more strongly correlated with insulin resistance than 
any other adipose tissue compartment (50, 51); other researchers claim that excess 
subcutaneous upper body fat has a significant association with insulin resistance (52, 53). 
In general, the pattern of upper body adiposity correlates more strongly with insulin 
resistance and lipid abnormality than lower body obesity. Elevated circulating free fatty 
acids are key factor that links upper body adiposity and insulin resistance (54, 55). 
The insulin resistance syndrome, which is synonymous to metabolic syndrome, 
defines the cluster of abnormalities that occur more frequently in insulin resistant 
individuals. These include glucose intolerance, dyslipidemia, endothelial dysfunction and 
elevated procoagulant factors, elevated inflammatory markers, abnormal uric acid 
metabolism, sleep-disordered breathing and increased ovarian testosterone secretion  
(56). Clinical syndromes associated with insulin resistance include type 2 diabetes, 
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essential hypertension, cardiovascular disease, non-alcoholic fatty liver disease, 
polycystic ovary syndrome, and certain forms of cancer and sleep apnea (49, 56). 
Ultimately, raised level of circulating free fatty acids is a chief factor that links 
obesity, dyslipidemia and insulin resistance (58, 59). The enlarging adipose tissue 
discharges high levels of FFA into the portal and systemic circulation (55, 60); this will 
result in accumulation of lipid in areas other than adipose tissue and the ectopic fat 
storage syndrome could occur. In muscles and liver, increased FFAs will promote insulin 
resistance (61, 62) and dyslipidemia (63). These FFAs decrease insulin sensitivity in 
muscle by inhibiting insulin signaling, glucose phosphorylation, glycogen synthase and 
pyruvate dehydrogenase (64, 58). Whereas, increases in free fatty acid flux to the liver 
will increase hepatic triglyceride synthesis. As a result of hypertriglyceridemia, a 
decrease in the cholesterol content of HDLc results from decreases in the cholesteryl 
ester content of the lipoprotein core (65). In addition, LDL composition will be altered to 
a small dense LDL resulting in increase of very low lipoproteins (VLDL) (66). This 
change in LDL composition is attributable to relative depletion of unesterified and 
esterified cholesterol, and phospholipids, with either no change or an increase in LDL 




Metabolic syndrome (MetS) 
The IDF considers the obesity epidemic to be one of the main drivers of the high 
prevalence of the MetS (45). Metabolic syndrome (MetS) is the name for a group of risk 
factors that increases the development of cardiovascular disease and Type2 diabetes 
mellitus (38). The metabolic risk factors including central obesity, atherogenic 
dyslipidemia, elevated plasma glucose, elevated blood pressure, prothrombotic and a 
proinflammatory state. In the effort of finding diagnostic tool for the metabolic syndrome 
(MetS) in clinical practice, several different sets of criteria have been recommended by 
different organizations for identifying patients with MetS. The more accepted of these 
definitions has been proposed by World Health Organization (WHO), the European 
Group for the Study of Insulin Resistance (EGIR), the American Association of Clinical 
Endocrinologists (AACE), the National Cholesterol Education Program- Adult Treatment 
Panel III (NECP ATP III), and International Diabetes Federation (IDF) (45, 68).  
The World Health Organization (WHO) definition considers insulin resistance as 
the major causal risk factor and requires its indicators [impaired glucose tolerance (IGT), 
impaired fasting glucose (IFG), type 2 diabetes mellitus, or impaired disposal of glucose 
under hyperinsulinemic, euglycemic conditions] for diagnosis. The presence of one of the 
several markers of insulin resistance and at least two of the following risk factors; 
obesity, hypertension, high triglycerides, reduced HDL cholesterol and microalbuminuria 
constitutes a diagnosis of metabolic syndrome. Patients with type 2 diabetes mellitus are 
at higher risk for cardiovascular disease (46). Therefore, the WHO group indicates the 
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term metabolic syndrome to be used in patients with Type2 diabetes who met the 
requirements for this syndrome (69). 
In 1999 the European Group for the Study of Insulin Resistance (EGIR) defined 
the syndrome in non-diabetic individuals who have hyperinsulinemia. They proposed to 
use fasting insulin levels to estimate insulin resistance, whereas plasma insulin levels in 
the upper quartile of the population will define insulin resistance. By their criteria, 
elevated fasting plasma insulin plus 2 other factors including abdominal obesity, 
hypertension, increased triglycerides, decreased HDL cholesterol and increased fasting 
plasma glucose will define metabolic syndrome. And if subjects were receiving treatment 
for hypertension or dyslipidemia they were considered to have the risk factor (70).  
The other important criteria came from the National Cholesterol Education 
Program (NCEP), Adult Treatment Panel III (ATP III) in 2001. These criteria do not 
include any measure of insulin resistance, which makes them more practical to use in 
epidemiological studies and clinical practice. In addition, these criteria do not emphasize 
a single cause and include waist circumference as the measure of obesity. The definition 
is based on the WHO criteria and requires the presence of at least three of five 
components including elevated triglycerides, reduced HDL cholesterol, hypertension, 
elevated fasting glucose and central obesity (71). Few years later, in 2005, the ATP III 
stated some modifications in metabolic syndrome definition including using lower waist 
circumference, including the medication use for high triglycerides, low HDLc and high 
blood pressure as the risk factor for these conditions even when their values are normal, 
and reducing the blood glucose thresholds for hyperglycemia from 110 mg/dL to 100 
mg/dL (72).  
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In 2003, the American Association of Clinical Endocrinologists (AACE) 
announced a position statement on insulin resistance syndrome. Major factors for 
identifying the insulin resistance syndrome are raised blood pressure, raised triglycerides, 
reduced HDLc cholesterol, raised fasting and post load glucose, and obesity. The 
diagnosis for the insulin resistance syndrome is based on clinical judgment. The AACE 
statement does not provide a specific number of factors for definition of this syndrome. 
Other factors used to decide the clinical judgment are: family history of CVD or type 2 
diabetes mellitus, polycystic ovary syndrome and hyperuricemia. By this definition the 
term “insulin resistance syndrome” can be applied after the person is diagnosed with 
Type 2 diabetes (68).  
In 2005, the International Diabetes Federation (IDF) proposed new criteria that 
modify ATP III definition. This definition requires the presence of abdominal obesity for 
diagnosis of syndrome. The justification for this requirement is that abdominal obesity is 
highly correlated with insulin resistance and other components of the syndrome. And it is 
a simple diagnostic tool to be use in clinical practice and research worldwide (67).  
Recently (2009), IDF and AHA/NHLBI representatives held discussions to 
attempt to resolve the remaining variations between definitions of metabolic syndrome. 
The establishment of a set of criteria, to be used worldwide is crucial, with agreed-upon 
cut points for different ethnic groups and sexes. This is crucial for international 
comparisons and to facilitate the etiology worldwide. Both sides agreed that abdominal 
obesity should not be a prerequisite for metabolic syndrome diagnosis. Instead abdominal 
obesity will be 1 of 5 criteria. Hence, the presence of any 3 of 5 risk factors constitutes a 
diagnosis of metabolic syndrome. All definitions agree on the key elements of the MetS 
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including obesity, insulin resistance, hypertension and dyslipidemia. However they 
provide different criteria and cut points to define this condition. The different criteria 
proposed for clinical diagnosis of metabolic syndrome are summarized in Table 1.  
IDF and AHA/NHLBI representatives believe that defining thresholds for 
abdominal obesity is complicated, in part as a result of differences in the relation of 
abdominal obesity to other metabolic risk factors in different ethnic groups. Moreover, 
predictive values for different levels of abdominal obesity for cardiovascular disease and 
diabetes could differ. Consequently, they demanded long-term prospective studies to 
reach more reliable waist circumference cut points for different ethnic groups, 
particularly for women (73). Table 2 lists current international recommendations 
projected by the IDF for thresholds of abdominal obesity to be used as 1 component of 
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Table 2. Current recommended waist circumference thresholds for abdominal obesity by 
organizations  
Population Organization  
Recommended Waist Circumference 
Threshold for Abdominal Obesity 
Men Women 
Europoid IDF (72) ≥94cm ≥ 80 cm  
Caucasian  WHO (14) 
≥ 94 cm  (increased risk)  
≥ 102 cm (still higher risk) 
≥ 80 cm (increased risk)  
≥ 88 cm (still higher risk)  
United States  AHA/NHLBI (ATPIII)* (76) ≥102 cm ≥ 88 cm 
Canada Health Canada (77, 78) ≥102 cm ≥ 88 cm 
European 
European Cardiovascular 
Societies  (79) 
≥102 cm ≥ 88 cm 
Asian (including 
Japanese) IDF 
(72) ≥ 90 cm ≥ 80 cm 
Asian WHO (80) ≥ 90 cm ≥ 80 cm 
Japanese Japanese Obesity Society (81)  ≥ 85 cm  ≥ 90 cm 
China Cooperative Task Force (82) ≥ 85 cm ≥ 80 cm  
Middle East 
Mediterranean IDF
 (72) ≥ 94 cm ≥ 80 cm 
Sub-Saharan African  IDF (72) ≥ 94 cm ≥ 80 cm 
Ethnic Central and 
South American  IDF
 (72) ≥ 94 cm ≥ 80 cm 
 *Recent AHA/NHLBI guidelines for metabolic syndrome recognize an increased risk for CVD and diabetes at waist-
circumference thresholds of ︎≥94 cm in men and ≥80 cm in women and identify these as optional cut points for 
individuals or populations with increased insulin resistance.  
 
The pathogenesis of metabolic syndrome and its components is multifarious and 
remains to challenge the professionals. The underlying risk factors for developing 
metabolic syndrome appear to be changeable such as, abdominal obesity (57, 83) 
physical inactivity (83, 84) and insulin resistance (85). Other related risk factors are 




Obesity and related cardiometabolic diseases in Saudi Arabia 
The Kingdom of Saudi Arabia (KSA) has witnessed a significant lifestyle shift 
over the last 60 years. The rapid modernization with the invasion of new lifestyle habits 
has resulted in rapid and progressive increase in the prevalence of obesity. KSA is ranked 
among the top 10 countries with regard to the prevalence of obesity (89). The IDF 
believes the obesity epidemic to be one of the key drivers of the high prevalence of the 
MetS. Obesity contributes to hypertension, hyperglycemia, high serum TGs, low HDL 
cholesterol and insulin resistance, and is associated with higher CVD risk (45).  
Overweight and obesity are emerging as major public health concerns in Saudi Arabia. 
The Saudi population seems to be the next victim of obesity since it has reached alarming 
level. The prevalence of obesity in Saudi Arabia has been reported to be about 14% in 
children up to 83% in adult. This wide variation due to the differences in criteria used to 
define obesity and due to the differences in age, sex, and health status of subjects in each 
study (90). According to recent national prevalence data of Saudis aged 15 years or older, 
around two thirds of adult women are either overweight (28.0%) or obese (33.5%). In 
contrast, 33.4% of the men are overweight and 24.1% are obese (10). 
Diabetes mellitus (DM) is highly prevalent in Saudi adults. In 2004, 23.7% of Saudi 
adult were found to be diabetic according to a national representative data (91). In 2013, 
Saudi Arabia has the 7th highest national diabetes prevalence (20.2%) world-wide (92). 
From recent data, in a nationally representative sample of more than 10 million Saudis 
aged 15 years or older, the prevalence of diabetes has been found to be 13.4 %.  
Interestingly, large percentage (43.6 %) of diabetic individuals were undiagnosed (93)  
!
! ! 18!
Hypertension (HTN) and borderline hypertension were highly prevalent in Saudi Arabia. 
15% Saudis aged 15 years or older had hypertension and 40.6%, or 5,222,051, had 
borderline hypertension. Besides, the data revealed high rates of undiagnosed 
hypertension (57.8%) (94). 
Cardiovascular diseases (CVDs) were the major cause of death (27%) for Saudi nation in 
2002 (95). Recent data revealed that, among Saudis aged 15 years or older, 5.4% reported 
that they were previously diagnosed with hypercholesterolemia. And 8.5% had 
hypercholesterolemia as measured by research’s laboratory tests with blood cholesterol 
level greater or equal to 6.2 mmol/L. However, 65.1% were undiagnosed or unaware of 
their condition. 19.6% of Saudis had borderline hypercholesterolemia with measured 
blood cholesterol levels between 5.18 and 6.2 mmol/L (96). 
Metabolic syndrome (MetS) according to the National Cholesterol Education Program-
Third Adult Treatment Panel (NCEP ATP III) was 35.3% (CI 33.5–37.01). Low HDL 
cholesterol was the most common MetS component with almost 9 out of 10 (88.6%) of 
subjects affected followed by hypertriglyceridemia with a prevalence of 34%. MetS 
prevalence increased with age, whereas individuals aged 50–55 years had MetS in almost 
6 out of 10 adults. (97). Another recent data used International Diabetes Federation (IDF) 
definition, reported MetS prevalence as 28.3% (98). 
High Prevalence of undiagnosed diseases is shocking in a country with free 
medical care and high resources. Indeed, these data call for action to control the burden 
of cardiometabolic diseases in the kingdom. A national plan to increase awareness, early 
detection, and control of cardiometabolic diseases is urgently needed (89). 
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Obesity Assessment tools 
Obesity is mainly diagnosed through calculating body mass index and sometimes 
through measuring body fat distribution; skinfolds, waist to hip circumference ratio, and 
waist circumference. Many studies have demonstrated that Neck circumference (NC) is a 
good predictor for obesity and cardiovascular disease in adults (20, 99, 100, 22). Other 
techniques, such as bioelectrical impedance, dual-energy x-ray absorptiometry, and total 
body water, can also be used for measuring body fat (13, 101). 
Body mass index (BMI)  
BMI is usually considered a surrogate marker of excess adiposity in terms of 
overweight and obesity (102, 103). The body mass index is a mathematical calculation 
used for determining whether a patient is overweight or obese, and is calculated by 
dividing a person's body weight in kilograms by the square of height in meter or by using 
the conversion with pounds (lbs) and inches (in) squared as shown below. Overweight is 
defined as a body mass index (BMI) between 25 and 29.9 kg/m2.  Obesity is defined as a 
BMI of 30 kg/m2 or higher (14) as in Table 3.  
BMI = weight (kg) ÷ Height (M2) or   




Table 3. Classification of BMI according to the WHO study group (2000) 
Obesity classifications BMI (kg/m2) 
Under weight  <18.5 
Normal weight 18.5 – 24.9 
Over weight 25 – 29.9 
Obese class I 30 – 34.9 
Obese class II 35 – 39.9 
Obese class III > 40 
 
This equation is fairly accurate for all individuals. However, BMI has some 
limitations as a measure of total body fat since its formula depends only upon weight and 
height, and it does not depict the true body composition. BMI may overestimates body fat 
in lean persons who are very muscular, in contrary under-estimates body fat in persons 
who have less muscle mass (15). BMI has been shown to be associated with 
cardiovascular diseases, diabetes and hypertension in Caucasians (104, 105, 106). 
Nevertheless, Caucasian people in the USA generally have a lower percentage of body fat 
for the same BMI than those in Europe (107). Also, Asians generally have a higher 
percentage of body fat than Caucasian people of the same age, sex, and BMI. Therefore, 
if the US prediction formula (108) is applied to these populations, the percentage of body 
fat is underestimated (109). In the same vein, a recent study in Saudi Arabia illustrated a 
significant limitation in using BMI alone to diagnosing obesity and its relative metabolic 
risk factors in the Saudi population. This study found an increased risk of hypertension 
and diabetes relative to BMI, starting at a BMI as low as 21 kg/m2, but overall there is no 
cutoff BMI level with high predictive value for the development of these chronic 
diseases, including the WHO definition of obesity at BMI of 30 kg/m2. The optimal BMI 
!
! ! 21!
cut-off points for overweight ranged from 28.50 to 29.50 for males and from 30.50 to 
31.50 for females depending on the risk factor being studied. These values are higher in 
general but, much higher in females than, BMI ≥25kg/m2, the values suggested by WHO 
(table 3). The authors stated several reasons for the failing of BMI as a tool to classify 
obesity; BMI does not reflect fatness uniformly in different populations and ethnic groups 
(110, 111, 112, 113) and Saudi women have short stature with a mean height of 1.54 m 
which could be the second reason for limiting the usefulness of BMI in this population 
(113).  
Waist-to-hip ratio (WHR) 
Historically, the waist-to-hip ratio is the most studied and well-established 
measurement of fat distribution (114). The cardiometabolic risks related to an increase in 
body weight and obesity are not limited to just increases in body fat mass but are also 
associated with body fat distribution. A specific area of interest is the upper-body fat 
mass relative to lower-body fat mass. This is generally assessed by a comparison of waist 
and hip circumference measurements and is expressed as the waist-to-hip ratio (WHR). 
Health risk increases with increase in upper-body fat (13). Waist-to-hip ratio (WHR) 
showed relatively strong correlations with total cholesterol, LDL-cholesterol and 
triacylglyceride concentration in both men and women (115). Bouchard (1991)(116) 
categorized obesity into four-types: 
Type 1 is characterized by a uniform body fat distribution; adipose tissue is not highly 
localized in any given region of the body. 
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Type 2 or android obesity is expressed as high accumulation of body fat in the trunk, 
primarily in the subcutaneous tissue regions. 
Type 3 represents individuals with excessive body fat in the abdominal viscera. 
Type 4 or gynoid shows localization of stores in the gluteofemoral region.  
Including the four categories, Types 2 and 4 represent the two most well known 
expressions of obesity. Type 2 or android obesity is often designated as the “apple”, due 
to the excess accumulation of adipose tissue in the upper body (trunk/ abdomen), giving 
the subject rounded appearance much like an apple. In contrast, type 4 or gynoid is 
known as the “pear”, with regional fat distribution on the lower body (hips, pelvis and 
lower extremities). WHR higher than 0.8 for women and 0.95 for men is defined as 
android obesity (117, 118, 119). Android obesity has been shown to be significant 
predictors of coronary heart disease (CHD) (120). In addition, Rebuffe et al (1990) 
considered that the android phenotype prone to high release of free fatty acids from intra-
abdominal depots, thus leading to altered metabolic functioning (121).  
Waist circumference (WC)     
In 1998 (122), the National Heart, Lung, and Blood Institute (NHLBI) in 
cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases 
have determined that waist circumference alone without hip measurement correlates 
better with biomarkers of health risk (e.g., hyperlipidemia, hyperglycemia, hypertension) 
and health outcomes (actual disease and mortality). Central adiposity increases the risk 
for cardiovascular and other diseases independent of obesity. Clinicians may use the WC 
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as a measure of central adiposity. The waist circumference cut-offs established by the 
NIH to identify those at increased risk were 
Men:  >102 cm (>40 in.) 
Women:  >88 cm (>35 in.) 
WHO agreed to the same cutoff points pronounced by NHLBI and considered 
them the most effective technique for assessing abdominal fat (14). According to WHO, a 
person will have: lower risk if WC is ≤ 79cm in women, ≤ 93cm in men; increased risk if 
WC is 80-87cm in women, 94-101cm in men; and substantially increased risk if WC is ≥ 
88cm in women, ≥102cm in men (14). The waist circumference thresholds are not 
reliable for patients with a BMI greater than 35 kg/m2 (123). Whereas, International 
Diabetes Federation established different cut-off points for different ethnic groups 
categorize as; a WC of > 97cm (37 in) for males, and >80 cm (34 in) for female Europids 
population; as well as WC of > 90cm (37 in) for males, and >80 cm (34 in) for female 
South Asians, Chinese and Japanese population (124) (table 2). European Cardiovascular 
Societies and Health Canada recommended that the threshold for waist circumference to 
define abdominal obesity should be higher as presented in Table 2 (77, 78, 79). Recent 
study in the Middle East showed that optimal WC cut-off point 85 cm for both sex in 
Tunisian population (125). Other studies at the Arabian Gulf region indicated that WC 
and WHR predict MetS risk better than BMI. The optimal WC cut-off points are 80.0 cm 
for men and 84.5 cm for women among Omani population (126). WC cutoff points for 
Iranian were (90 cm for men and 90.3 cm for women) and for Iraqi were (97 cm for men 
and 99 cm for women) (127, 128). Beside, in Qatar, men WC at a cut-off 99.5 cm 
resulted in the highest sensitivity (81.6%) and specificity (63.9%). In women, WC at a 
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cut-off 91 cm resulted in the highest sensitivity and specificity of 86.5% and 64.7%, 
respectively (129).   
WC is reported as a cardiometabolic predictor in literature, yet it has some 
drawbacks. For individuals with a BMI ≥ 35, waist circumference adds little to the 
predictive power of the disease risk classification of BMI (130). The risk prediction of 
WC is influenced by the anatomic location of measurement, especially in women. 
Accordingly, the choice of measurement protocol may bias research findings and 
influence clinical decision-making. Mason and Katzmarzyk (131), emphasized that until a 
uniform approach to the measurement of WC is widely agreed, the location of 
measurement should be an important consideration in the interpretation of WC 
measurements (131, 26). Waist circumference accuracy is limited in some situations, 
including pregnancy, medical conditions where there is distension of the abdomen, such 
as ascitic, or reduction of the abdomen, such as abdominal liposuction or tummy tuck 
(Abdominoplasty) (27). The main limitation of the WC measure is the huge inter-ethnic 
variability that arises for certain ethnic groups and for children and young people. Special 
threshold for WC is being recommended in several different populations and ethnic 
groups (presented in table 2). Whereas, the risk associated with a particular WC will 
differ in different populations. This is especially relevant in a country without local cut 





Neck Circumference as an indicator of cardiometabolic risk factors  
Obesity is well known to cause metabolic abnormalities. The distribution of 
excess adipose tissue may be considered to be more important than total fat in conferring 
metabolic and cardiovascular risk (132). Upper-body obesity is more associated with 
glucose intolerance, insulin resistance, diabetes, hypertriglyceridemia, and uric calculous 
disease than is lower-body obesity (20). Visceral adipose tissue (VAT) is acknowledged 
as a unique pathogenic fat depot. Elevated VAT may indicate metabolic risk over 
assessments provided by standard anthropometric measures, such as body mass index 
(BMI) and waist circumference (WC) (133). Large amount of VAT increases risk of 
certain obesity related complications, such as insulin resistance, type 2 diabetes, and 
atherosclerosis (134, 135). Nevertheless, some studies showed that VAT accounts for 
only modest correlations with cardiometabolic risk factors, implying that other 
mechanisms, or other fat depots, may also contribute to the development of 
cardiovascular disease (CVD) risk factors (18, 133). Upper body fat distribution has long 
been recognized as correlated to increased cardiovascular disease risk, where neck 
skinfold (117) or neck circumference (NC) (136, 137) has been used as an index for such 
an adverse risk profile. Moreover, free fatty acid release from upper body subcutaneous 
fat depots (SAT) was reported to be larger than that from lower body subcutaneous fat or 
from visceral adipose tissue, suggesting that this fat depot may play a considerable role in 
risk factor pathogenesis (138, 53). Raised free fatty acid concentrations have been 
associated with insulin resistance, increased very low density lipoprotein cholesterol 
production, and endothelial cell dysfunction (139). The strong correlation between SAT 
and cardiometabolic risk factors may be determined by the results from some (140, 141, 
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142) but not all studies (143, 144). Neck circumference is a proxy measure for upper 
body subcutaneous fat depots (SAT), and the association has been examined. Among 258 
men from the control group of the Fat Redistribution and Metabolic Change in HIV 
Infection study, upper body section fat was found to be independently associated with 
insulin resistance even after adjustment for VAT (145). In another study of 145 control 
participants from the Fat Redistribution and Metabolic study revealed that increased 
levels of upper-body section fat were positively associated with LDL cholesterol and 
inversely associated with HDL cholesterol levels, after adjustment for demographic and 
lifestyle factors (146). According to the Framingham Heart Study, neck circumference is 
a proxy of upper-body section fat, and is a novel, discrete, and pathogenic fat depot both 
independent of and synergistic with VAT (18). While the adjustment for VAT diminishes 
the association between neck circumference and cardiometabolic risk factors, it is 
essential to note that most associations remained statistically significant (18). Neck 
circumference is correlated with body mass index (BMI) and cardiovascular risk factors 
(147, 21). Some studies have demonstrated that neck circumference may be an 
independent correlate of metabolic risk factors even above and beyond BMI and waist 
circumference (148, 21). While other presented the neck circumference as a simple, time-
saving and cost effective measure to assess overweight and obesity, especially during 
winter and in busy primary care practice (20). Several studies have examined the 
association between neck circumference and cardiometabolic risk factors. Neck 
circumference has been compared directly with VAT with respect to their association 
with cardiometabolic risk factors. Neck circumference is considered an index of upper 
body obesity and associates positively with changes in systolic and diastolic blood 
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pressure and other components of the metabolic syndrome (22). Neck circumference has 
been found to be a good clinical predictor of insulin resistance, menstrual irregularity, 
infertility, hirsutism, and the Polycystic Ovarian Syndrome (PCOS) (100). A cross-
sectional study among 1912 Turkish adults, estimated neck circumference as an indicator 
of central obesity.  And even with the adjustment for sex- and age, neck circumference 
was significantly associated with metabolic syndrome (MetS) and obstructive sleep apnea 
syndrome (OSAS) in both genders.  WC has higher independent association with MetS.  
While both neck circumference and WC were reported to share significant independence 
of association with OSAS whereby neck circumference appeared to be a superior marker 
in men and WC in women (21). In contrast, another study found a greater association of 
neck circumference with cardiometabolic risk factors in women as compared with men. 
According to a cross-sectional analysis of 541 Finnish individuals, neck circumference in 
the highest quintile was associated with nearly a 5-fold increased risk of impaired fasting 
glucose in women after adjustment for BMI. No association was seen for men. Neck 
circumference was also found to be associated with approximately a 3-fold increase of 
hypertension, after adjustment for BMI, in both men and women (100). A cross-sectional 
study of 4053 Chinese subjects reported neck circumference is independently correlated 
with Fatty liver disease (FLD). The participants with FLD had significantly higher neck 
circumference levels and other anthropometric measures (body weight, WC, HC, BMI 
and WHR) in both men and women compared with non-FLD participants. Consistently, 
the FLD participants had higher fasting blood glucose, blood pressure, blood uric acid, 
triglycerides, total cholesterol, apolipoprotein B, and apolipoprotein E, as well as alanine 
transaminase (ALT), aspartate transaminase (AST) and γ-glutamyl transpeptidase (GGT). 
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Moreover, even after adjusting for age, logistic regression analysis presented a strong 
positive association between neck circumference and FLD in both men and women. 
Whereas, after additional adjusting for BMI and WC, the corresponding ORs were 
attenuated to 1.94–2.53 (P <0.001) in women and 1.45–2.08 (P <0.001) in men. And neck 
circumference cut off points of 38 cm in men and 34 cm in women had the optimal 
sensitivity and specificity to predict subjects with FLD (149).  
The available up to date cut-off points of neck circumference for determining 
subjects with overweight, obesity, and metabolic and cardiovascular disease risks are 
presented in the following table. 
Table 4. Current recommended neck circumference cutoff points for overweight, 
obesity, and metabolic syndrome risks by literature. 
Study Year Country n. 
Male Female 
Over-wt Obese Abd-obesity 
MetS 





Ben-Noun et al. (20) 2001 Israel 253 ≥ 37cm ≥ 39.5cm   ≥ 34cm ≥ 36.5cm   
Onat et al. (21) 2009 Turkey 1912   38.5cm   39cm   34.5cm    35cm 
Yang et al. (147) 2010 China 3182 ≥ 38cm   ≥ 39cm ≥ 35cm   ≥ 35cm 
Hingorjo et al. (150) 2012 Pakistan 155 > 35.5cm > 37.5cm   > 32cm > 33.5cm   
Kumar et al.!(151) 2012 India 203     >37cm    >34cm 
Zhou et al. (152) 2013 China 4201    >37cm    >33cm 
Stabe et al. (27) 2013 Brazil 1053    >40cm    >36.1cm 
El Din et al. (153) 2013 Egypt 6718 ≥ 38cm ≥40.25cm   ≥ 36cm  ≥37.25cm   
Aswathappa et al. (154) 2013 India 1351  >36cm  >38cm  >32cm  >34cm  
Kumar et al. (155) 2014 India 431    >37cm    >34cm 
Yan et al. (156) 2014 China 2092  >38cm  >38cm  >35cm  >35cm 
Limpawattana et al. (157) 2016 Thailand 589    >39cm      >33cm 




Possible biological mechanisms 
Obesity is no longer viewed as a single disease, but rather as a complex condition 
manifested in multiple expressions or phenotypic forms. For example, two obese 
individuals, though similar in height, age and weight, may not appear exactly alike. One 
individual may carry more weight on his upper body (trunk/ or abdominal), while his 
counterpart exhibits a heavier weight distribution in the lower extremities. This has led 
researchers to establish a classification scheme, to determine how these various 
expressions may alter a patient’s disease and mortality profile (114). Whereas, the 
android phenotype prone to high release of free fatty acids that lead to altered metabolic 
functioning. Literatures strongly suggest that free fatty acids are an important link 
between obesity and insulin resistance. Some studies have reported that is due to upper 
body/visceral adipose tissue (144), while others have established that upper 
body/subcutaneous fat is responsible for higher release of free fatty acids (140, 141, 142, 
158). The excess free fatty acid release, associated with upper body/subcutaneous fat, has 
been suggested to be one mechanism that clarifies the association between 
cardiometabolic risks and neck circumference (18). The inability of insulin to adequately 
suppress FFA release from upper body subcutaneous fat is the major defect in upper body 
obesity (158, 159) and Type2 diabetes (160). It is well recognized, however, that high 
levels of FFA can mediate insulin resistance in muscle (161, 162) and liver (163, 164). 
As a result of the failure to suppress FFA, inhibition of carbohydrate oxidation and 
glycogen synthesis in muscle during hyperinsulinemia (165), reduction in the clearance 
of insulin by the liver (166), and elevation in VLDL-triglyceride production (167) will 
occur. The other potential mechanism might be related to upper body fat (168, 169), 
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which could be estimated by the neck circumference (170, 18). The excess FFAs increase 
oxidative stress, thereby triggering the inflammatory response and progressive liver 
damage. Stojiljkovic et al. (171) reported that an acute raise in plasma lipids increased the 
concentration of the oxidative stress biomarker F2-isoprostanes and raised the possibility 
of the cardiovascular risk factor cluster. These observations might illuminate the 
mechanism by which an elevated neck circumference independently increases the risk of 
cardiometabolic risks and the developing fatty liver disease. (Fig. 1)  
  
Figure 1. Mechanisms linking a hypertrophic neck with the development of fatty 
liver disease 
- Source: Huang BX et al. (149) 
!
! ! 31!
Chapter 2: Methods  
Study Design 
A cross-sectional survey was conducted in King Khalid University Hospital 
(KKUH) primary health care centers in Riyadh city, Kingdom of Saudi Arabia, during 
September 2014 - April 2016, using a total of 700 adults aged 18-70 years. 
Study setting 
The study was conducted in the city of Riyadh. Riyadh is the capital and largest 
city of Saudi Arabia, with a population of approximately 5 million. Whereas, 65% are 
Saudi and 35% are non-Saudi. The city is located in the center of the Kingdom of Saudi 
Arabia (Riyadh Principality). The study setting consisted of primary health care center of 
King Khalid University Hospital (KKUH) in Riyadh city. This setting was selected for 
carrying out the study as a surrogate for a population-based study that would be ideal for 
the recruitment of study subjects, but was challenging given the limited time and 
resources. The attendants of KKUH setting actually represented the Saudi population in 
Riyadh since any Saudi was eligible for getting primary care services at this center 
regardless of any personal or socio-demographic, or economic factors. Moreover, the 





Study population  
The target population for this study consisted of all Saudi men and women aged 
18-70 years who attended KKUH primary health care center in Riyadh city during the 
time of the study. Inference from the sampling to the target population might be possible 
if we can assume that Saudi men and women who attended primary health care center 
were not different from other Saudi population living in Riyadh, whether they used 
primary health care center services or not. This assumption may need to be evaluated 
through comparing the basic socio-demographic characteristics in the study sample with 
the corresponding national indicators. If statistically significant differences were 
revealed, the study findings would only be inferred to men and women in the sampling 
population. 
A written consent was obtained from each of the clients about their willingness to 
participate, after explaining the purpose of the study, to assure that information would be 
kept confidential  and used strictly for research purpose. 
Eligibility criteria  
This study enrolled subjects with the following criteria:  Saudi men and women 
aged 18-70 years old. 
Subjects with the conditions below were excluded from the study:  
! Pregnant and lactating women. 
! Having thyroid nodule. 
! Having serious diseases (i.e. Organ Failure, Transplant, Cancer)  
! Having impaired-decision capacity or mental illness.  
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Sample size calculations  
Power: In order to determine the appropriate sample size for the study, an 
analysis of statistical power was performed (172). Statistical power is the probability that 
the Null Hypothesis, when the null hypothesis is false, will be rejected.  For a specific 
statistical procedure, the likelihood of rejecting the Null Hypothesis is a function of: a) 
the alpha level for testing the Null Hypothesis; b) the effect size for the independent 
variable or variables being tested; and c) the sample size.  By fixing the alpha level and 
effect size, the sample size needed to attain a desired power level could be 
determined. Sample size computations for the present study assumed that the statistical 
tests would be conducted at alpha = 0.05, and that the independent variable had a 
moderate effect size (equivalent to a correlation of .3) (175).  Sample sizes were 
computed to attain a more lenient level of power (Beta = 0.80) as well as a more stringent 
one (Beta = 0.95).  A power level of 0.80 is considered acceptable for an exploratory 
study.  At this power level, there is an 80% probability of rejecting the Null Hypothesis 
when the assumed effect size is true.  A power level of 0.95 is considered necessary for a 
more definitive study in which the costs of retaining a false Null Hypothesis are 
greater.  With a power level of 0.95, there is a 95% probability of rejecting the Null 
Hypothesis if the assumed effect size is true.   
In this study, the computations of the sample sizes needed to attain the 0.80 and 
0.95 levels of statistical power were performed using the G*Power3 software package 
(173).   For the analyses involving partial correlations, there was a need for between 
84 and 138 subjects for each gender. For analyses within a multiple regression framework 
with ten predictors, there was a need for between 172 and 245 subjects for each 
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gender.  For the logistic regression analyses, we needed between 600 and 1200 subjects 
for each gender.  
As for the discrimination between normal and subject at cardiometabolic risk, the 
sample size was calculated based on the accuracy of a test calculation. It depended on the 
following (174): 
• Type I error - alpha: (α-level, two-sided) 
• Type II error - (β-level) 
• Area under ROC curve: the hypothesized Area under the ROC curve (the AUC 
expected to be found in the study). 
• Null hypothesis value: the null hypothesis AUC. 
• Ratio of sample sizes in negative / positive groups. In this work, the negative is the 
normal subject and the subject with cardiometabolic risk is the positive.  
The following table presents the sensitivity analysis for sample size calculations for ROC 
curve using the MedCalc® Version 12.5.0.0 statistical software package 







0.05 0.2 0.8 0.5 3/1 9 27 
0.05 0.1 0.8 0.5 3/1 12 36 
       
0.05 0.2 0.75 0.5 3/1 14 42 
0.05 0.1 0.75 0.5 3/1 18 54 
       
0.05 0.2 0.7 0.5 3/1 22 66 
0.05 0.1 0.7 0.5 3/1 29 87 
       
0.05 0.2 0.65 0.5 3/1 39 117 
0.05 0.1 0.65 0.5 3/1 52 156 
       
0.05 0.2 0.6 0.5 3/1 86 264 




ROC curve area of 0.7 was determined to be 88 (n=22+66).  
 
Eventually, based on the primary outcome measure of differences in 
cardiometabolic risks on neck circumference, the sample size of 600, for each gender, 
was determined to have 80% power with two-tailed significance level of 5% to detect a 
moderate effect size. The sample sizes was estimated to be large enough for the 
regression analysis with 10 or more independent variables according to Hsieh et al., 1998 
(176). The calculation was performed using the G*Power3 software package (173), and 
MedCalc® Version 12.5.0.0 statistical software package.  
Sampling technique  
Ideally, subjects should be selected by systematic random sampling from the 
patients' registers in KKUH primary health care center. A sampling frame would thus be 
constructed (separate by gender) according to the eligibility criteria, and then a 
systematic random sample is recruited with the periodicity of selection determined by 
dividing the total eligible population by the required sample size. Then, the selected 
persons would be contacted and invited to participate. We found that this process is not 
feasible in a conservative community, and would lead to considerable selection bias due 
to non-response. Therefore, the sampling frame was constructed from the daily booking 
logs of the center. Names and file numbers of all Saudi men and women ages 18-70 years 
were obtained first in the morning. Then, the systematic random sampling technique was 
used to select participants from these frames.  We used the following formula for 
systematic sampling: K ≤ N/n. whereas; the population size (N) is the number of total 
eligible population (Saudi males and females aged 18-70 years) and the required sample 
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size (n) was chosen based on the power calculation. Therefore, n=700, and the total 
eligible population were N=4,167. The formula then became 5.9 ≤ 4167/700. In order for 
systematic sampling to be valid, the first item was randomly selected from the first K 
items in the daily booking logs until the target sample size of 700 was achieved. We then 
looked at every 6th subject from KKUH primary health care center.  
In the case of rejection or if participant did not meet the study criteria, the next 
adjacent participant was selected.  This has been done for all 5-days of the week in each 
center to avoid any bias related to the days of the week. At the end of each day, the list 
form (personal identifier) was destroyed.  Yet, we do keep a list of the participants file 
numbers only to avoid taking or selecting them again in the future. 
Then, researchers rescreened the selected persons for eligibility using the 
screening tool (Appendix 1; 1A-Arabic version and 1B-English version). If eligibility 
criteria were met, the participants were invited to participate, provided with informed 
written consent (Appendix 2), and asked to answer questions, on a volunteer basis, with 
estimated time of 10-15 minutes in order to complete the survey (Appendix 3; 3A-Arabic 
version and 3B-English version). The selected subjects were asked to participate one time 
only. All procedures and required data were fully explained. They were assured that they 
would not be identified and the information would strictly be used for the purpose of this 
research study.  
Data Collection 
This work have been done in collaborative work with Biomarkers Research 
Program(BRP), King Saud University, Riyadh (KSA), data collection was carried out by 
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the researcher and her team over a period of 18 months from September 2014 to April 
2016. The Ethics Committee of the King Saud University, Riyadh, Kingdom of 
Saudi Arabia and University of Maryland College Park Institutional Review Board (IRB) 
approved the study (Appendix 4).  
The data collection tools included an interview questionnaire, anthropometric 
measurement, clinical assessment, and blood biochemical tests.  
I. Interview Questionnaire 
For collecting data for the study, a pre-coded interview questionnaire was 
designed. Since Arabic is the primary language among Saudi people, the questionnaire 
has been designed in Arabic then translated into English language. Prior to using the 
Arabic questionnaire, the researcher carried out a pilot study in the waiting area of the 
same primary health care center. The aim was to test the clarity of the questions and the 
time needed for the interview. The pilot consisted of a convenience sample of 26 clients 
(11 Men and 15 women) aged 18 to 51 years. All those invited to participate gave their 
oral consent. Based on the participant responses and the clients’ ability to understand, 
some questions were modified, excluded and added to the questionnaire. The time spent 
in the interview averaged 15 minutes. The pilot sample was not included as a part of the 
actual study sample. 
The questionnaire was judged for its face validity through review by experts in 
nutrition and behavior sciences, students in the Master’s and PhD programs in Nutrition 
and Food Science department at University of Maryland College Park, USA, as well as 
the research supervisors.  The questionnaire is entitled “Overweight and obesity 
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assessment tool.” The questionnaire consists of five parts: socio-demographic data, 
medical history, dietary habit and practices, physical activity and lifestyle as well as 
anthropometric measurements and blood test results (Appendix 3; A-Arabic versions and 
B-English versions). Each subject who agreed to participate will be interviewed in an 
empty room to provide an atmosphere of comfort and trust.  
a) Socio-demographic data 
Socio-demographic variables including age, gender, education level, marital 
status, number of children, occupation, average monthly income level, smoking 
statues, and previous participation in research study were assessed using “Overweight 
and obesity assessment tool” questionnaire (Appendix 3). 
Education levels was categorized as illiterate, read and write, elementary, 
intermediate, secondary, graduate, post- graduate and further categorized to five 
strata: illiterate, less than high school (including read and write, elementary, 
intermediate), completed high school or diploma (secondary), bachelor degree and 
higher education. Marital status was categorized as unmarried, married, separated, 
divorced, widowed and further divided into two categories as married (including 
living as married), and unmarried (including being widowed, divorced, separated, or 
never married). While, the occupation was categorized as unemployed (housewife), 
student, teacher, office work, business, medical doctor, nurse, millenarian, and retired. 
The economic status was assessed by total monthly family (household) income (less 
than 1,999; 2,000 SR - 4,999 SR; 5,000 SR – 7.999 SR; 8,000 SR -10,999 SR; 11,000 
SR - 13,999 SR; 14,000 SR -16,999 SR; 17,000 SR - 19.999 SR; More than 20.000 
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SR; and unknown). And further categorized to four strata: less than 9,999 SR; 10,000 
SR to 19,999 SR; more than 20,000 SR∗; and unknown. Smoking (cigar, pipe, shisha 
[water pipe or flavored tobacco]) was categorized as never smoked (if they had 
smoked <100 cigarettes in their lifetime), former smoker (≥100 lifetime cigarettes, not 
currently smoking), and current some day smoker (≤100 lifetime cigarettes, currently 
some day smoking), and current every day smoker (≥100 lifetime cigarettes, currently 
very day smoking). And further categorized to two strata: non smoker (if they had 
smoked <100 cigarettes in their lifetime) and smoker (≥100 lifetime cigarettes in their 
lifetime) (177)  
b) Family Medical History / Health History Data 
Family history of chronic diseases and conditions: Subjects were considered 
to have a family history of chronic diseases or condition if any of their biological 
(blood) relatives, living or deceased, including grandparents, parents, brothers, and 
sisters had obesity; diabetes; hypercholesterolemia; hypertension; or cardiovascular 
diseases. Subjects with a previous diagnosis of diabetes, hypercholesterolemia, 
hypertension, or cardiovascular diseases were determined. Treatment for previously 
diagnosed hypertriglyceridemia, hypercholesterolemia, and diabetes were identified. 
For female, the age of the first menstrual cycle, menopausal, and hormonal therapy 
were specified. Females were also asked if they ever used hormone or hormone 
therapy (yes vs. no). Menopausal status was categorized as last month (regular 





12 consecutive months and further defined as: premenopause if menses had occurred 
in the past 12 months; postmenopause if menses had stopped for at least 12 months 
(178, 179). 
c) Dietary habit and practices 
Data about subjects dietary habits and practices were ascertained by 15 questions 
about regularity of daily meals, meal skipping, snacks intake, snack of different types and 
at different times, fruits and vegetable consumption, use of sweeteners, fats, dairy 
products, food preparation, and consumption of fast foods. The questions in section were 
modified after existing reliable questionnaires (180, 181, 182). Eleven dietary practice 
questions were scored from 1 to 3 with higher score for more healthy practices. 
Alpha reliability coefficient (Cronbach’s alpha) for dietary habit and practice 
instrument or scale was 0.54.  We improved the consistency by removing the lowest 
correlated variable. And the finale Cronbach’s alpha was 0.72. 
d) Physical activity and life style 
A special physical activity assessment questionnaire (Activity Records) was 
modified after RENO Diet-Heart Study (RDHS) quoted from (Harrington, 1997) and 
 The total dietary habit and practice scores ranged from 11 - 33, and only in the 
descriptive table, were leveled as follows: 
Good practices  26- 33 
Fair practices  18-25 
Poor practices  11-17 
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used for assessing participants, physical activity practices about regularity and intensity 
(183). Four questions were included about physical activity types, times per week, 
session’s time per minutes, and sedentary leisure time during the last entire year were 
scored as follows.   
! The total score was calculated by summing the regularity score, intensity score, and 
lifestyle score.  
Scoring the regularity of physical activities:  
Sedentary (Never) 1 
 
Irregularly Active (Some time) 2 
 
Regularly Active (Always) 3 
 
 
Scoring of physical activities at differing intensity levels per week (183,184):  






150 -279 minutes of walking 
Less than 60 minutes of running, swimming, cycling, aerobic, 






More than280 minutes of Walking 
More than 60 minutes of running, swimming, cycling, aerobic, 
and resistance exercise 
! Scoring of daily activities (lifestyle) at differing levels (180, 184): 
Very Sedentary 1 Typing, reading, and watching TV 
Sedentary 2 Cleaning, shopping 
Moderate Active 3 Hard job 
Very Active 4 Swimming, cycling 
!
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The total score was ranged from 2 - 10 and, only in the descriptive table, was 
divided into tertiles, where the lowest one will be referred to as “sedentary physical 
activity level”; the medium one, referred to as “partially moderate physical activity 
level”; and the highest one, referred to as “active physical level” (185). 
Alpha reliability coefficient (Cronbach’s alpha) for Physical activity and life style 
levels instrument or scale was 0.740. 
II. Anthropometric Measurements 
The anthropometric measurements have been conducted according to the 
Anthropometry Procedures Manual proposed by the National Health and Nutrition 
Examination Survey 2002 (186). Six variables were selected for anthropometric 
measurements, height, weight, body mass index (BMI), neck circumference (NC), waist 
circumference (WC), hip circumference, waist-hip ratio (WHR) and body fat (%). All 
anthropometric measurements were taken by a well-trained health care provider (clinic in 
charge nurse), who was instructed to use the same technique of weight and height 
measurements for all subjects of the study sample.  
The height was recorded to the nearest 0.5 cm, by using a height scale 
measurement, with the subject standing upright barefooted or in thin socks and 
bareheaded. The weight was recorded to the nearest 0.1 Kg, with appropriate 
international standards scales, by using standardized beam weight scales (Detecto scale, 
Cardinal Scale Mfg. Co., USA). A 5 kg standard weight was used daily for assessing and 
adjusting the scales (scale calibration). Weight was taken without shoes and with light 
clothing. Body mass index (BMI) was calculated by the equation: BMI = Weight in Kg / 
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(Height in meters)². According to the World Health Organization's BMI additional cut-off 
points categorization, participants were classified into: normal weight (≤24.99 kg/m2), 
over-weight (25 kg/m2 to 29.99 kg/m2), and obese (≥30 kg/m2) (109).  
A Gulick II® fiberglass tape measure, (Country Technology, Gays Mills, WI) 
model # 67020, was used to measure neck circumference (NC), waist circumference 
(WC), hip circumference. Neck circumference was measured to the nearest 0.1 cm, with 
the participants standing erect and their head positioned in the Frankfort horizontal line 
(facing forward). The tape measure was then placed horizontally at the midway of the 
neck between mid-cervical spine and mid-anterior neck, just below the laryngeal 
prominence (Adam’s apple) (18, 20).  Waist and hip circumferences were measured, with 
the participants in the standing position and in light clothing (social reason), to the 
nearest 0.5 cm by using a flexible measure tape. The reading was taken to the nearest 0.1 
cm with the tape ensured to be snug, but not compressing the skin. Waist circumference 
(cm) was measured at mid-point between bottom of the rib cage and above the top of 
iliac crest. Hip circumference (cm) was measured at widest point of the 
buttocks.   Waist-to-hip ratio (WHR) was calculated by dividing the waist 
circumference (cm) by the hip circumference (cm). WHO and IDF recommended that 
different WC cutoff points should be used to define central obesity among different 
ethnic groups, and that the Europid standards should be used in our Eastern 
Mediterranean region until specific national data become available (45, 73). WC cut-off 
points are currently categorized as: a WC of > 97 cm (37 in) for males, and >80 cm (34 
in) for females for Europids population (70, 72, 124).  
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Body fat percentage (%) was assessed by using a dual-energy X-ray 
absorptiometry (DEXA) device (model: Prodigy Advance, GE healthcare). DEXA is a 
scanning technique that measures bone mineral, fat tissue, and fat-free soft tissue. 
Subjects must lie completely still on the DEXA machine platform while X-rays at a high 
and low energy levels are passed over the body (187, 188). After completing the doctor 
visit, the subject was asked to visit the radiology department within the same center. 
Well-trained radiologic technologists performed the DEXA scan, with estimated time of 
15-20 minutes in order to be completed. This procedure was not painful, but there could 
be some minor discomfort from lying in the same position. This discomfort was 
minimized by keeping the time involved in making the measurements as short as 
possible, and by allowing the subject a break if necessary. 
III. Clinical & Biochemical Parameters 
The parameters determined were: fasting plasma level of glucose (FPG), insulin, 
triglycerides (TG), total cholesterol (TC), HDL cholesterol (HDLc), and LDL cholesterol 
(LDLc); as well as blood pressure.  
! Blood Pressure Measurement: before starting the measurement, subjects were 
seated quietly for a five-minute period. The subjects were not allowed to smoke or 
drink coffee during the examination since these could affect the blood pressure. If the 
subject has had any coffee, or cigarettes thirty minutes before the examination, this 
was recorded on the form but the measurements were still taken. The right arm was 
used for standardization and consistency. Measurement was taken using standardized 
mercury sphygmomanometers (Diplomat Presameter 660-360 manufactured by 
!
! ! 45!
Riester GMBH, Germany). Blood pressure was considered normal if systolic BP < 
130 mm Hg and diastolic BP < 85 mm Hg (38).  
! The agreed to participate subjects were scheduled for a second visit to the laboratory 
in the same clinic within one week. They were informed to attend after fasting for 10-
12hrs. Samples were analysed and stored in the Biomarkers Research Program 
(BRP), College of Science, King Saud University (KSU), Riyadh, Saudi Arabia. In 
brief, all blood and serum samples were placed in plain polystyrene tubes, delivered 
on the same day to BRP and stored at −20°C. Fasting blood glucose and lipids (total 
cholesterol, triglycerides and HDL cholesterol) were measured using a standard 
chemical analyzer (hexokinase and colorimetric methods, respectively) (Konelab, 
Vantaa, Finland) under strict conditions. The analyser was recalibrated frequently 
according to manufacturer’s instructions. LDL-cholesterol was estimated by using the 
Friedewald equation = [Total Cholesterol] - [HDL cholesterol] - ([Triglycerides]/2.2) 
(189).  Insulin concentrations were determined by electro-chemiluminescence method 
(COBAS-E-411; Roche Diagnostics, Mannheim, Germany). Homeostasis model 
assessment for insulin resistance (HOMA-IR) was then calculated for all patients 
using the HOMA formula:  HOMA-IR= fasting insulin (µU/mL) × fasting plasma 
glucose (mmol/L) /22.5. (190, 191)  
Variables of Interest 
The variables of interest were grouped as described earlier into the following 
categories: socio-demographic including age, gender, education level, marital status, 
number of children, occupation, average monthly income level, smoking statues; dietary 
habit; Physical activity; anthropometric; biochemical; and cardiometabolic risk factors. 
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Cardiometabolic risk factors 
Biomarkers of cardiometabolic diseases (cardiometabolic risk factors) are defined 
according to the International Diabetes Federation IDF definition guidelines (38) as 
follow: central obesity (94 cm ≥ for men, 80 cm ≥ for women), hypertriglyceridemia 
(triglycerides ≥1·7 mmol/L), low HDL cholesterol (<1·03 mmol/L for men and 1·29 
mmol/L for women or specific treatment for this lipid abnormality), hyperglycemia 
(fasting plasma glucose ≥5·6 mmol/L or previously diagnosed type 2 diabetes), and 
hypertension (systolic BP ≥ 130 mm Hg, diastolic BP≥ 85 mm Hg or treatment for 
previously diagnosed hypertension). Metabolic syndrome are defined as per (IDF, 
NHLBI, AHA, IAS, IASO) harmonized definition guidelines (73) with the presence of 
any three or more of the following risk factors: raised triglycerides (≥1·7 mmol/L), 
reduced HDL cholesterol (<1·03 mmol/L for men and 1·29 mmol/L for women or 
specific treatment for this lipid abnormality), raised fasting plasma glucose (≥5·6 mmol/L 
or previously diagnosed type 2 diabetes), raised blood pressure (systolic BP ≥ 130 mm 
Hg, diastolic BP≥ 85 mm Hg) or treatment for previously diagnosed hypertension. Insulin 
resistance was assessed by using a homeostasis model assessment (HOMA-IR) [fasting 
glucose (mmol/l) X fasting insulin (µmol/mL)/ 22.5] (190). 
Assessment of Covariates 
The information on covariates and potential confounders such as: age (y), 
smoking habit [non smoker (if they had smoked <100 cigarettes in their lifetime) and 
smoker (≥100 lifetime cigarettes in their lifetime) (173)], physical activity (sedentary 
physical activity level, partially moderate physical activity level, active physical 
level)(185), menopausal status [premenopause if menses had occurred in the past 12 
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months; postmenopause if menses had stopped for at least 12 months (177, 179)], current 
estrogen use (no vs. yes), treatment for previously diagnosed hypertriglyceridemia (no vs. 
yes), hypercholesterolemia (no vs. yes), and diabetes (no vs. yes) were included in the 





Descriptive statistics was applied for all variables. Continuous data were 
presented as mean ± standard deviation (SD) and Median (25th -75th) percentiles for 
variable following Gaussian and Non Gaussian variables. Categorical variables were 
presented as frequencies (n) and percentages (%). All Continuous variables were checked 
for normality using graphs, Kolmogorov-Smirnov test, as well as Skewness and Kurtoses 
(≤0.8). If they were not normal, the continuous variables were transformed to log or 
SQRT transformation, where it was appropriate. The frequency distribution of each 
variable at baseline was compared in men and women by using chi-square ( ) or Fisher 
exact tests, as suitable for categorical variables.  Student t-test and Mann-Whitney U test 
were used for Gaussian and Non Gaussian variables. All analyses involving insulin 
measures (insulin, and HOMA-IR) were restricted to participants without diabetes. 
Relationships among variables were sought by Partial correlations and performed 
between the study variables. The findings were expressed as correlation coefficients and 
P-Value, after controlling for: age in men. And controlling for: age; menopausal status 
(premenopausal vs. postmenopausal); and current estrogen use (no vs. yes) for women. 
Analyses were performed separately for each gender. Regression and ROC curve 
analyses were performed for women only, because of the low sample size in men. Neck 
circumference, WC, BMI, and fat% were standardized in women to a mean of zero and a 
SD of one to facilitate the comparisons of the regression coefficients. Linear regression 
analysis was performed, considering the cardiometabolic risk factors (Log Fasting 
glucose, SQRT Insulin, SQRT HOMA-IR, SQRT Triglycerides, HDLc, LDLc, SBP, 
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DBP) as dependent variables, as well as considering neck, body mass index, waist 
circumference, and body fat percentage as independent variables.  
Multiple binary logistic regression analysis was performed, with the consideration 
of the cardiometabolic risk factors: central obesity (present/absent), hypertriglyceridemia 
(present/absent), low HDLc (present/absent), high LDLc (present/absent), hyperglycemia 
(present/absent) and hypertension (present/absent), HOMA-IR >75th (present/absent), the 
presence of two or more of the risks, metabolic syndrome as per the harmonized criteria 
(the presence of three or more of the risks), metabolic syndrome as per the IDF criteria 
(the presence of abdominal obesity and two or more of the risks) as dependent variables 
and the neck circumference as independent variables and control for covariates. Then 
participants were classified into quartiles (Q1–Q4), with Q1 (<25th percentile) as the 
reference. Multivariate logistic regression analysis was used to calculate odds ratios 
(ORs) and 95% confidence intervals (CI) for cardiometabolic risks according to the neck 
circumference quartiles after adjusting for covariates. Multicollinearity among 
independent variables and between confounders was tested in regression model by 
examining variance inflation factor (VIF) and tolerance. No variable with VIF greater 
than 10 or tolerance less than 0.01 was detected.  
Receiver operating characteristic (ROC) curves were used to determine the 
efficacy of neck circumference as screening measure for correctly identifying subjects 
with cardio metabolic risks and to select appropriate sex-specific cut-off points for neck 
circumference (192). The optimal cut-off points for women were determined using the 
Youden index (J), and calculated as: J = maximum (sensitivity + specificity -1) and the 
shortest distance between any point on the curve and the top left corner on the y-axis. The 
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distance on ROC curve values were calculated as the square root of [(1-sensitivity) 2 + (1-
specificity) 2] (192).  
The additive interaction between neck circumference and other anthropometric 
measurements was evaluated using logistic regression analysis, as suggested by Rothman 
et al. (147, 193,194, 195), with 3 indices: the relative excess risk due to interaction 
(RERI), the attributable proportion due to interaction (AP) and the synergy index (S) with 
95% CI. If there was no additive interaction, 95% CI of RERI and AP were equal to 0, 
and S equal to 1 (Appendix 5).  
Statistical analyses were performed using SPSS 22 (IBM Corp., Armonk, 
NY, USA). All tests were 2-sided, and levels of statistical significance were set at p-





Chapter 3: Results 
Participants 
The study was carried out at the King Khalid University Hospital (KKUH) 
primary heath care center. Participants were Saudi men and women between 18–70 years 
of age. Of the 922 subjects initially identified for study inclusion, 66 declined to 
participate, as being too busy or not interested. Seventy-one (71) subjects were excluded 
for one of the following reasons: age, pregnancy, or lactating. In addition, 85 subjects 
were excluded because they did not show up for their blood tests. Seven hundred (700) 
subjects, 18 years of age or older, with no known major medical issues, were enrolled in 
the study. The study sample consisted of 623 women and 77 men.  
Socioeconomic and behavioral characteristics of the study subjects 
The results of Table 5 show that only 3% of the participants were <25 years of 
age, 9% were between 25–34 years of age, 19% were between 35–44 years of age, 43.3% 
were between 45–54 years of age, and 25.6% were ≥55 years of age. The mean ages of 
men and women were significantly different as 53±8.7 and 47±10.7 years old, 
respectively. As compared to the men, 26.3% of female participants were illiterate and 
17.5% had graduate and post-graduate qualifications.  While in men, 41.5% were at least 
high school educated, 45.5% had a bachelor’s degree, and 10.4% had graduate and post-
graduate qualifications.  
The majority of the sample, amounting to 71.2% (n=497), reported being married, 
while 6% were single, 9.8% were separated or divorced, and 13% were widowed. The 
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data for the women showed that 41.4% had more than six children, 31.8% had four to six 
children, 14.7% had three children or less, while 12.1% had no children. A considerable 
proportion of the women (31.2%) were unemployed. Most of the participants, amounting 
to 22.4% and 25.9% of men and women, respectively, were office workers. In addition, 
28.9% of men and 14.5% of women were retired. Most of the men did not respond to the 
income question (86.8%), and 40.6% of female participants had less than a 10,000 Saudi 
Riyal (SR) monthly income. Only 6.5% of the women had more than a 20,000 SR 
monthly income*.  
Data presented in Table 5 shows that nearly 40.3% of men and 63.5% of women 
had fair dietary habits and practices. Only 0.4% of the subjects had a good dietary habits 
and practices. The total physical activity score showed that 72.7% of men and 55.5% of 
women had a poor physical activity and lifestyle level. In addition, 15.6% of men and 
34.7% of women had a fair physical activity and lifestyle level. However, only 10% of 






Clinical and biochemical characteristics of the study subjects  
The participants’ clinical and biochemical characteristics by gender are shown in 
Table 6. The average body mass index (BMI), hip circumference (HC), and body fat 
percentage were higher for the women (P<0.00). Men were taller, heavier, and had larger 
waist circumference (WC), waist hip ratio, and neck circumference (NC) values (all 
P<0.05). The differences in weight and WC seem to be due to age rather than gender 
differences (not significant after age adjustment). 
The cardiometabolic biomarkers data indicate that men had greater values for 
blood pressure, fasting blood glucose (P<0.001), triglycerides (TG), as well as HOMA-
IR and insulin (P<0.05), and lower high density lipoprotein cholesterol (HDLc) 
(P<0.001), as compared to women. Consistently, after the age adjustment, systolic blood 
pressure (SBP) and triglycerides no longer showed a significant difference (Table 6).  
The prevalence of cardiometabolic risk factors and medical history of the study 
population are summarized in Table 7. Cardiometabolic risk factors (high blood pressure, 
high fasting glucose, high triglycerides, and being in HOMA-IR ≥75th percentile) were 
found to be significantly higher in men as compared to women (P<0.01). However, 
abdominal obesity, and low HDLc were more prevalent in women (P=0.001). More than 
seventy percent (70.9%) of the population had metabolic syndrome. The prevalence 
according to the harmonized definition (84.4% in men and 69.3% in women, P<0.01) 
was higher than the IDF definition in both genders. Nearly half of the population (44.8%) 
had hypertension. In contrast, only 14.3% had reported that they had been previously 
diagnosed with hypertension. Family history of diabetes mellitus was more prevalent in 
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men (P=0.01) (Table 7).  
Neck circumference and the other obesity indices 
Scatter plot matrixes in Figures 3 and 4 show fair to moderate positive linear 
correlation between neck circumference and BMI, and WC, in both genders. The scatter 
around the line is quite small, except for body fat percentage. 
As shown in Table 8, the partial correlation coefficient was used to examine the 
correlation of neck circumference with body fat percentage, BMI, and WC after 
controlling for the effects of age. BMI showed the highest correlation with WC, as 
compared to its correlations with other clinical indices (!=0.676, n=584 in whole sample; 
r=0.765, n=70 in men; r=0.697, n=514 in women; all !<0.001). Neck circumference and 
WC were highly correlated in both men and women (r=0.537 in men and r=0.607 in 
women; P<0.001 for both). All correlation coefficients of neck circumference and WC 
with the clinical indices were highly significant among men and women (P<0.01).  
The men were also divided into subgroups based on their BMI. The BMI cutoffs, 
as per WHO criteria (109) were normal weight (≤24.99 kg/m2), over-weight (25 kg/m2 to 
29.99 kg/m2), and obese (≥30 kg/m2). Correlation coefficients of neck circumference and 
WC with the clinical indices were varied in the subgroups (Table 9). Each BMI subgroup 
was further divided into three subgroups based on 25th, 25–75th, and 75th percentiles of 
WC. Neck circumference data showed increases from the lower WC subgroups to the 
higher WC subgroups within each BMI subgroup. The only exception was in the over-
weight groups, where the neck circumference value for the WC>75th percentile was not 
different than that of the WC 25th–75th percentile group (Figure 5). No man in the obesity 
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subgroup was below the 25th percentile for WC. Although the sample size for men is low, 
this figure was presented for reference. 
After further adjustment for postmenopausal status and hormone use in women, 
all women were divided into subgroups based on their BMI. Neck circumference and WC 
were significantly correlated in the overall sample (r=0.605) and in the three BMI 
subgroups (r=0.511, r=0.410, r=0.514) (all P<0.01) (Table 10). Each BMI subgroup was 
further divided into three subgroups based on 25th, 25–75th, and 75th percentiles of WC. 
In women, neck circumference significantly increased from the lower WC subgroups to 
the higher WC subgroups within each BMI subgroup (Figure 6). Interestingly, no woman 
in the normal weight subgroup was above the 75th percentile of WC.  
Neck circumference and cardiometabolic risk indicators in women 
Table 11 presents the age, menopausal status, and hormone use adjusted 
correlation coefficient between all anthropometric indices and cardiometabolic risk 
factors used in this study for the whole sample and per BMI. With the exception of body 
fat percentage, all other indices were correlated with systolic blood pressure (SBP), 
diastolic blood pressure (DBP), high density lipoprotein (HDL), triglycerides (TG), 
insulin, and HOMA-IR. For the whole sample, neck circumference was positively 
correlated with all cardiometabolic risk factors except for total cholesterol and low 
density lipoprotein (LDL) (P<0.001). Moreover, compared to body fat percentage, BMI, 
and WC, neck circumference has the highest correlation with all cardiometabolic risk 
factors for the whole sample and in the overweight and obese groups, but not in the 
normal group (Table 11). 
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After controlling for the effects of age, menopausal status, hormone use, dietary 
habits and practices, as well as physical activity and lifestyle in women, multivariate 
regression analyses were used to examine the independent association of neck 
circumference with cardiometabolic risk factors. Table 12 illustrates the results of the 
multivariate regression analyses conducted by using separately each cardiometabolic risk 
factor as the dependent variable, while all listed covariates were entered in first block of 
the model. In the second block, the independent variable (neck circumference) was added 
to the model. Neck circumference was associated with all risk factors, except for LDL 
cholesterol (Models 1). After further adjustment for BMI (Models 2), R-squared changes 
were slightly increased for fasting glucose and total cholesterol (0.041, 0.016, 
respectively). On the other hand, the R-squared changes were attenuated for SBP, DBP, 
HDLc, insulin, and HOMA-IR, but still remained significantly associated with all risk 
factors. For example, among women, an incremental increase in neck circumference of 1 
standard deviation (SD) was associated with a 4.87 mm Hg increase (P<0.001) in SBP in 
the primary model. Upon further adjustment for BMI (Models 2), the increase in SBP 
became 4.33 mm Hg (P<0.001) per 1 SD incremental increase in neck circumference. In 
Models 3, which adjusted for WC, the neck circumference β-coefficients were also 
increased for DBP, fasting glucose, and total cholesterol. The R-squared changes were 
attenuated for SBP, DBP, triglycerides, HDLc, insulin, and HOMA-IR, but remained 
highly statistically significant for all risk factors (all P<0.001 except for TC and HDLc, 
P<0.05). In Models 4, which adjusted for BMI and WC, the R-squared changes showed 
the same trend as the previous models 3 and 4 (that adjusted for BMI or WC). In Models 
5, which adjusted for BMI, WC, and body fat percentage, the predictive power, as 
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adjusted R-squares, for these models were the highest. However, the R-squared change 
increased only for fasting glucose (R2 change=0.048, P<0.001) (Table 12). Moreover, in 
Table 13, regression models were constructed by considering cardiometabolic risk 
factors separately as dependent variable, and BMI, WC, NC, and body fat percentage 
were the four independent variables (entered in the second block). All confounders (age, 
postmenopausal status, hormone use, dietary habits and practices, physical activity and 
lifestyle, and the medications intake) were controlled (entered in the first block). Neck 
circumference showed the highest β-coefficients for all risk factors except for HDLc and 
LDL cholesterols (P<0001 for all, P<0.01 for total cholesterol). 
Figures 7 to 13, present an analysis of the interaction between tertiles of neck 
circumference and BMI subgroups (normal, overweight, and obese) on cardiometabolic 
risk factor levels in women. Within each subgroup of BMI, there was a stepwise increase 
in risk factor levels by tertiles of neck circumference. There was no significant interaction 
between neck circumference and BMI for cardiometabolic risk factors except for insulin 
(P=0.015) and HOMA-IR (P=0.041) (Figures 12 and 13).  
Neck circumference contribution in the prediction of cardiometabolic 
conditions 
Multiple logistic regression analyses were used to estimate the odds ratios (OR) for 
the development of the cardiometabolic risk factors [central obesity (WC ≥80 cm for 
women), hypertriglyceridemia (triglycerides ≥1.7 mmol/L or specific treatment for lipid 
abnormality), low HDLc (<1.29 mmol/L for women or specific treatment for this lipid 
abnormality), high LDLc (≥4.12 mmol/L or specific treatment for lipid abnormality), 
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hyperglycemia (fasting plasma glucose ≥5.6 mmol/L or previously diagnosed Type 2 
diabetes) and hypertension (systolic BP ≥130 mmHg, diastolic BP ≥85 mmHg or 
treatment for previously diagnosed hypertension), HOMA-IR >75th (present/absent), 
metabolic syndrome as per the harmonized criteria (the presence of three or more of the 
risks), metabolic syndrome as per the IDF criteria (the presence of abdominal obesity and 
two or more of the risks)] according to the increment increase in neck circumference, and 
controlling for age, menopausal status, and hormone use (Table 14, Figure 13). Elevated 
neck circumference was associated with increased ORs of metabolic syndrome and all 
cardiometabolic risk factors, except for LDLc (all P<0.0001). After the further adjustment 
of BMI, WC, and body fat percentage, neck circumference remained the independent 
predictor of all binary cardiometabolic risk factors (all P<0.05).  
To determine the dose-response of enlarging neck circumference with 
cardiometabolic risk, quartiles of neck circumference were derived (cut points for NC 
were <35 cm, 35 cm–36.5 cm, 36.6 cm–38 cm, >38 cm). The ORs and 95% confidence 
interval (CI) for metabolic syndrome and its components according to quartiles of neck 
circumference are presented in Table 15. The ORs of metabolic syndrome or its 
components increased from the 1st to the 4th quartile of neck circumference (P-trend, 
<0.001 for all). Compared with women in the lowest neck quartile, those in the highest 
quartile had ORs of 8.76 (95% CI: 5.13, 14.96) for hypertension, 15.28 (95% CI: 7.95, 
29.36) for elevated fasting plasma glucose, 4.38 (95% CI: 2.67, 7.18) for elevated 
triglycerides, 3.54 (95% CI: 2.08, 6.02) for reduced HDLc, 3.54 (95% CI: 2.08, 6.03) for 
elevated LDL cholesterol, 3.10 (95% CI: 1.63, 5.84) for elevated HOMA-IR, 6.34 (95% 
CI: 3.65, 11.01) for obesity, 27.01 (95% CI: 11.87, 61.46) for central obesity, 17.13 (95% 
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CI: 8.38, 34.99) for having two or more cardiometabolic risks, and 17.98 (95% CI: 8.79, 
36.78) for metabolic syndrome (all P<0.01) (Model 1). After adjustment for age, 
menopausal status, and hormone use (Model 2), similar trends were found in the risk of 
the components of metabolic syndrome across increasing quartiles of neck 
circumference, except the Q4 group for high HOMA-IR (all P< 0.01). Women in the 
highest neck circumference quartile were 12 times more likely (95% CI: 5.67, 26.47) to 
have two or more metabolic risk factors when compared to the lowest neck 
circumference quartile. Moreover, women with the largest neck were 13 times more 
likely (95% CI: 6.35, 28.23) to have metabolic syndrome when compared to the lowest 
neck circumference quartile and after adjustment for the mentioned confounders (all 
P<0.01).  
Optimal cut-off points to predict cardiometabolic risks  
The receiver operating characteristic (ROC) curves were presented in Figures 14 
–17. For metabolic syndrome, neck circumference presented the largest area under the 
curve compared with WC, BMI, and body fat percentage in women, which were 0.796 
(0.757–0.836) for neck circumference, and 0.711 (0.667–0.756), 0.659 (0.612–0.706), 
and 0.587 (0.532–0.642), respectively, for WC, BMI, and body fat percentage (all 
P<0.001, except for body fat percentage, where P<0.01).  
According to the ROC curve analysis, the optimal neck circumference cutoff 
values with the highest Youden index (maximum sensitivity and specificity) for 
predicting the presence of three or more metabolic risk factors was NC=36 cm, Youden 
index=0.468. However, the shortest distance on the ROC curve from perfect predictor 
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was for NC=35 cm, distance in ROC curve=0.323. We determined that NC=35.5 cm, 
with distance in ROC curve=0.327, and Youden index=0.450, should be our neck 
circumference cut-off point. The accuracy, sensitivity, and specificity of this cutoff were 
75%, 78.7%, and 66.3%, respectively (Table 16).  
To define the optimal WC cutoff values, we located a WC cutoff with the highest 
Youden index (maximum sensitivity and specificity) for predicting the presence of two or 
more metabolic risk factors (WC=95.5cm, Youden index=0.319). Since IDF criteria 
require the presence of central obesity for the diagnosis of metabolic syndrome, we 
justified choosing a cutoff point that obtains a higher sensitivity. Therefore, we 
determined that WC=92 cm, with the shortest distance in ROC curve=0.434 and a 
Youden index=0.318, is our WC cutoff point. This cutoff point has better sensitivity 
(78.1%) and accuracy (70.7%). The specificity of this cutoff was 53.7% (Table 17).  
Therefore, the appropriate neck circumference and WC to predict metabolic 
syndrome in the Saudi female population were 35.5 cm and 92 cm, respectively. 
Moreover, 27.7 kg/m2 for women emerged as the optimal cutoff point for BMI with 
maximum sensitivity and specificity for predicting the presence of three or more 
metabolic risk factors , Youden index=0.254 and distance in ROC curve=0.504, with a 
sensitivity and specificity of 84.9% and 40.5%, respectively (Table 18).  
Prevalence of metabolic syndrome 
After applying the modified WC of 92 cm for women, we observed a 23% 
reduction in the prevalence of central obesity (94.2% to 71.3%). The prevalence of 
metabolic syndrome as per the harmonized definition in women also decreased from 
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69.3% to 61.7%. A higher reduction was observed in the prevalence of metabolic 
syndrome as per the IDF definition (Table 19).  
When dividing the subjects according to neck circumference dichotomized by 
35.5 cm in women, the prevalence of metabolic syndrome, obesity, and central obesity 
were all significantly higher in the above group (≥35.5 cm) than those in the below 
groups (<35 cm) (Table 20).  
We further examined the combined effects between NC (<35.5 cm vs. >35.5 cm, 
women) and WC (<92 cm vs. >92 cm) or BMI (<25 kg/m2 vs. >25 kg/m2) in predicting 
metabolic syndrome using a stratified analysis (Figures 18, 19, and further details 
available in Appendix 5). In the women with high neck circumference values, the ORs 
(95% CI) of metabolic syndrome for the group with high WC, or BMI, were 8.27 (4.97–
13.78), and 11.09 (5.17–23.83), respectively (all P<0.001), which were much greater than 
those of 1.48–1.91 in the women with low neck circumference values. A high neck 
circumference value was associated with a significantly greater risk of metabolic 
syndrome, even in participants with a normal WC or BMI. In addition, the combined 
effects between NC (<35.5 cm vs. >35.5 cm, women) and WC (<80 cm vs. >80 cm) in 
predicting metabolic syndrome revealed very high ORs (95% CI) of metabolic syndrome 
for the group with high neck circumference and high WC, 23.18 (6.57–81.78). It is 
interesting to find that no women with a small WC had a large neck circumference 
(Figure 20). 
The additive interaction of neck circumference and other anthropometric 
measures on metabolic syndrome was evaluated. The relative excess risk due to 
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interaction (RERI) of neck circumference vs. WC or BMI was 2.05(-6.16 - 10.26), and 
3.7(-11.6 - 19.01), respectively. The attributable proportions due to interaction (AP) 
values were 0.25(-0.07 - 0.57) and 0.33(-0.89 - 1.55). The synergy indices (S) were 
1.39(0.88 - 1.9), and 1.58(0.202 - 3.677), respectively. These indicated the absence of an 
additive interaction between neck circumference and other anthropometric measures on 


















Assessed for eligibility  
(n=922)  
Lost to "no show" for laboratory visit; 
(within one week)(n=85) 
Final Sample 
(n=700) 
Declined to participate (n=66)  
(too busy, not interested) 
Excluded; Not meeting inclusion 
criteria (n=71)  
(age, pregnancy, lactating, having 














Age in years    
< 25   21 (  3.0)   0 (00.0)   21 (  3.4) 
25-34   62 (  9.0)   1 (  1.3)   61 (  9.9) 
35-44 132 (19.1)   9 (11.9) 123 (20.0) 
45-54 299 (43.3) 34 (44.7) 265 (43.0) 
>55 177 (25.6) 31 (40.8) 146 (23.7) 
Marital Status:    
Unmarried   42 (  6.0)   6 (  7.9)   37 (  5.9) 
Married 497 (71.2) 63 (82.9) 434 (69.7) 
Separated or divorced   68 (  9.8)   2 (  2.6)   66 (10.6) 
Widowed   91 (13.0)   5 (  6.6)   86 (13.8) 
Number of parity¥:    
None      72 (12.1) 
One      12 (  2.0) 
2-3      76 (12.7) 
4-6    190 (31.8) 
More than 6    247 (41.4) 
Education level:    
Illiterate 166 (23.7)   2 (  2.6) 164 (26.3) 
Less than high school 287 (41.1) 32 (41.5) 255 (40.9) 
Completed high school or diploma 130 (18.5) 35 (45.5)   95 (15.3) 
Bachelor degree or higher education 117 (16.7)   8 (10.4) 109 (17.5) 
Occupation:    
Unemployed (Housewife) 196 (28.1)   2 (  2.6) 194 (31.2) 
Student   10 (  1.4)   0 (  0.0)   10 (  1.6) 
Teacher   36 (  5.2)   4 (  5.3)   32 (  5.1) 
Office work 178 (25.5) 17 (22.4) 161 (25.9) 
Business   37 (  5.3)   9 (11.8)   28 (  4.5) 
Medical Doctor     3 (  0.4)   0 (  0.0)     3 (  0.5) 
Nurse     5 (  0.7)   0 (  0.0)     5 (  0.8) 
Militaries   11 (  1.6) 11 (14.5)     0 (  0.0) 
Retired 112 (16.0) 22 (28.9)   90 (14.5) 
Other 110 (15.8) 11 (14.5)   99 (15.9) 
Monthly Family Income:    
Less than 10,000 257 (37.0)   6 (  8.0) 251 (40.6) 
10.000 SR - 19.999 SR   96 (13.8)   4 (  5.2)   92 (14.9) 
More than 20.000 SR   40 (  5.8)   0 (  0.0)   40 (  6.5) 
Un known – No response 301 (43.4) 66 (86.8) 235 (38.0) 
Dietary habits and practice: 
Poor 
 
46 (59.7) 224 (36.0)  270 (38.6) 
Fair  427 (61.0) 31 (40.3) 396 (63.5) 
Good      3 (  0.4)   0 (  0.0)     3 (  0.5) 
Physical activity and life style levels:  
Poor  402 (57.4) 56 (72.7) 346 (55.5) 
Fair  228 (32.6) 12 (15.6) 216 (34.7) 
Good    70 (10.0)   9 (11.7)   61 (  9.8) 







































Age in years 
691 
47.9 ± 10.6 
75 
52.6 ±   8.7 
616 







155.6 ±   7.4 
77 
167.4 ±   6.9 
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77 
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32.1 ±   6.2 
76 
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0.9 ± 0.09 
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1.2  ±   0.3 
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L)  ★ 
353 
1.9  (1.2- 3.2) 
22 
2.4 (1.4-  7.6) 
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1.9 (1.2-  3.1) 
0.049 
0.026 
★Excluding diabetes subjects 
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Table 7. Biochemical and medical characteristics of the study subjects 
Categorical characteristics 
Metabolic risk factors1: 






! ! ! ! ! ! !
Waist circumference (cm)  699 651 (93.1) 76 64 (83.1) 623 587 (94.2) 0.001 
High blood pressure (mmHg) 699 313 (44.8) 76 47 (61.0) 623 266 (42.7) 0.002 
High fasting glucose (mmol/L) 2 683 472 (69.1) 77 67 (87.0) 622 406 (65.3) 0.000 
High triglycerides (mmol/L) 2 685 309 (45.1) 77 45 (58.4) 619 264 (42.6) 0.010 
Low HDL cholesterol (mmol/L) 2 688 465 (67.9) 75 38 (49.4) 613 427 (68.9) 0.001 
High total cholesterol (mmol/L) 2 695 270 (38.8) 77  24 (31.2) 618 246 (39.8) 0.172 
High LDL cholesterol (mmol/L) 2 697 257 (36.9) 77 20 (26.0) 620 237 (38.2) 0.044 
HOMA-IR ≥75th Percentile3  349 103 (29.5) 24 15 (62.5) 325   88 (27.1) 0.001 
Medical history: 
Laboratory results        
Pre-diabetes4 
Fasting glucose 6.1-6.9 (mmol/L) 683   82 (19.7) 76  6 (  7.9) 607   45 (  7.4) 0.000 
Diabetes5 
Fasting glucose >7(mmol/L) 683 385 (56.3) 76 60 (78.9) 607 298 (49.1) 0.000 
Hypertension  700 313 (44.7) 77 47 (61.0) 623 266 (42.7) 0.002 
Reported by subjects        
Pre-diabetes  697   46 ( 6.6) 77   0 (  0.0) 620   46  ( 7.4) 0.006 
Diabetes  697 337 (48.3) 77 50 (64.9) 620 287 (46.2) 0.002 
Hypertension  700 100 (14.3) 77   2 (  2.6) 623   98 (15.7) 0.001 
Treatments: 
Diabetes treatment 700 362 (51.7) 77 50 (64.9) 623 285 (45.7) 0.006 
Cholesterol treatment 700 218 (31.1) 77 14 (18.2) 623 204 (32.7) 0.005 
Triglycerides treatment 700   76 (10.8) 77   6 (  7.8) 623   70 (11.2) 0.584 
Metabolic syndrome (harmonized) 6  699 496 (70.9) 77 65 (84.4) 622 431 (69.3) 0.006 
Metabolic syndrome (IDF) 7  699 489 (69.9) 77 61 (79.2) 622 428 (68.8) 0.060 
Current cigarette smoker 700   11 (  1.6) 77   6 (  7.8) 623     5 (  0.8) 0.001 
Postmenopausal¥    - 623 162 (26.0) - 
Current hormone use¥    - 623   33  ( 5.3) - 
Family history of 
cardiometabolic diseases:        
Diabetes 692  76 60 (78.9) 616 388 (63.0) 0.006 
Hypertension 695  77 33 (42.9) 618 269 (43.5) 0.911 
Dyslipidemia 683  77   4 (  5.2) 606   71 (11.7) 0.119 
Heart diseases 697  77   5 (  6.5) 620   56 (  9.0) 0.668 
Stroke 698  77   0 (  0.0) 621   16 (  2.6) 0.240 
Note: The frequencies of categorical variables were compared in men and women using Chi square and Fisher exact test 
where appropriate. 
¥ Women only; 1) Using IDF criteria; 2) high levels or medications use ; 3) Excluding diabetes subjects; 4) Fasting glucose: 
6.1-6.9(mmol/L); 5) Fasting glucose: >7(mmol/L) or taking diabetes medications as per ADA ; 6) Metabolic syndrome 
(harmonized definition) as having 3 or more of the following (WC, TG, HTN, HDLc, GLUC); 7) Metabolic syndrome (IDF 




Figure 3. Scatter plot matrix of the correlation of anthropometric indices in men   
 
BMI= body mass index; WC= waist circumference; NC= neck circumference; Fat %= body fat %. 
NC (cm) vs BMI kg/m2, R2linear=0.452; NC (cm) vs WC (cm), R2linear=0.367; NC (cm) vs body fat%, R2linear=0.150.  
WC (cm) vs BMI kg/m2, R2linear=0.593; WC (cm) vs body fat%, R2linear=0.217.  
BMI kg/m2 vs body fat %, R2linear=0.276.  
!
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Figure 4. Scatter plot matrix of the correlation of anthropometric indices in 
women   
 
BMI: body mass index; WC: waist circumference; NC: neck circumference; Fat%: body fat%.!
NC (cm) vs BMI kg/m2, R2linear=0.278; NC (cm) vs WC (cm), R2linear=0.404; NC (cm) vs body fat%, R2linear=0.123.  
WC (cm) vs BMI kg/m2, R2linear=0.489; WC (cm) vs body fat%, R2linear=0.192. 
BMI kg/m2 vs body fat %, R2linear=0.313.! !
!
69!










































































































































orrelation adjusted for age (years). D
ata presented as coefficient (R); * denotes significance at 0.05 level; ** denotes significance at 0.01 level; *** 
denotes significance at 0.001 level. 
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Table 12. The associations of neck circumference with metabolic and 




Variables  β (SE) 
P-Value Adjusted R2 R Square 
Change 
SBP a 
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   0.037** 
   0.028** 
   0.026** 
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DBP a 


























   0.080** 
   0.054** 
   0.055** 
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   0.052** 
Glucose# b 









  0.035(0.006) 
  0.044(0.007) 
  0.045(0.008) 
  0.047(0.008) 
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Triglyceridesv c 
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Cholesterol d 








  0.121(0.041) 
  0.154(0.048) 
  0.157(0.051) 
  0.165(0.052) 
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    0.016* 
    0.015* 
    0.016* 
    0.014* 
HDL cholesterol d 



























    0.014* 
    0.009* 
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    0.006  
LDL cholesterol d 
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Insulin v e  





























    0.093** 
    0.087** 
    0.074** 
BMI= body mass index; WC= waist circumference; NC= neck circumference; SBP= Systolic BP (mm Hg); DBP= Diastolic BP (mm Hg); TC= 
Total Cholesterol (mmol/L); TG= Triglycerides (mmol/L); FG= Fasting glucose (mmol/L); HDLc= high density lipoprotein cholesterol (mmol/L) 
LDLc= low density lipoprotein cholesterol (mmol/L; HOMA-IR= homeostasis model assessment of insulin resistance (mmol/L × μU/mL). Model 
1: one dependent (cardiometabolic risk factor), one independent (NC) (in the second block), controlling for confounders (age, dietary habit & 
practices, activity level & life style, postmenopausal status, and hormone use) (in the first block). Model 2: one dependent, one independent 
(NC) (in the second block), controlling for confounders (age, dietary habit & practices, activity level & life style, postmenopausal status, hormone 
use, and BMI) (in the first block). Model 3: one dependent one independent (NC) (in the second block), controlling for confounders (age, dietary 
habit & practices, activity level & life style, postmenopausal status, hormone use, and WC) (in the first block). Model 4: one dependent, one 
independent (NC) (in the second block), controlling for confounders (age, dietary habit & practices, activity level & life style, postmenopausal 
status, hormone use, BMI, and WC) (in the first block). Model 5: one dependent, one independent (NC) (in the second block), controlling for 
confounders (age, dietary habit & practices, activity level & life style, postmenopausal status, hormone use, BMI, WC and Fats (in the first 
!
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block).  Additionally adjusted for (a) Hypertension treatment (b) diabetes treatment, (c) hyperlipidemia treatment (d) Hyper cholesterol. (e) 
Excludes individuals with diabetes. # Log and v SQRT transformed values. 
R square change is the amount of the increase in predictive power after entering the NC to the model (second block).  * denotes significance at 
0.05 level; ** denotes significance at 0.01 level; *** denotes significance at 0.001 level.! !
!
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Table 13. The associations of anthropometrics indices with metabolic and 
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BMI= body mass index; WC= waist circumference; NC= neck circumference; SBP= Systolic BP (mm Hg), DBP= Diastolic BP 
(mm Hg), TC= Total Cholesterol (mmol/L), TG= Triglycerides (mmol/L), FG= Fasting glucose (mmol/L), HDLc= high density 
lipoprotein cholesterol (mmol/L), LDLc= low density lipoprotein cholesterol (mmol/L), HOMA-IR= homeostasis model 
assessment of insulin resistance (mmol/L × μU/mL). 
Models are: one dependent (cardiometabolic risk factor) and four independents (BMI, WC, NC, Fat %) (in the second block),  
controlling for confounders (age, dietary habit & practices, activity level & life style, postmenopausal status, and hormone 
use) (in the first block). Additionally adjusted for (a) Hypertension treatment (b) diabetes treatment, (c) hyperlipidemia 
treatment (d) Hyper cholesterol. (e) Excludes individuals with diabetes. # Log and v SQRT transformed values. 
R square change is the amount of the increase in predictive power after entering the NC to the model (second block).  * 
denotes significance at 0.05 level; ** denotes significance at 0.01 level; *** denotes significance at 0.001 level.! !
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Figure 7. Systolic blood pressure levels by neck circumference and body mass 
index subgroups for women 
!
                                        Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck 
circumference levels (tertiles); all means are adjusted for age (years), postmenopausal, hormones use; ** Denotes 
significance post hoc analysis at 0.01 level; *** denotes significance at 0.001 level. 
NC= neck circumference!
Figure 8. Diastolic blood pressure levels by neck circumference and body mass 
index subgroups for women 
!
                                      Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck circumference levels (tertiles); 
all means are adjusted for age (years), postmenopausal, hormones use; ** Denotes significance post hoc analysis at 0.01 level; *** 
Denotes significance at 0.001 level.   
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Figure 9. Total Cholesterol levels by neck circumference and body mass index 
subgroups for women  
!
                                     Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck 
circumference levels (tertiles); all means are adjusted for age (years), postmenopausal, hormones use.  
NC= neck circumference !
!
Figure 10. SQRT triglycerides levels by neck circumference and body mass index 
subgroups for women 
 
                                              Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck circumference levels (tertiles); 
all means are adjusted for age (years), postmenopausal, hormones use; * denotes significance post hoc analysis at 0.05 level; ** denotes 
significance at 0.01 level; *** denotes significance at 0.001 level.! 















































Figure 11. Log fasting glucose levels by neck circumference and body mass 
index subgroups for women 
!
                                     Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck circumference levels (tertiles); 
all means are adjusted for age (years), postmenopausal, hormones use; * denotes significance post hoc analysis at 0.05 level; ** denotes 
significance at 0.01 level; *** denotes significance at 0.001 level.! 
NC= neck circumference 
Figure 12. HDL cholesterol levels by neck circumference and body mass index 
subgroups for women 
!
                                     Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck 
circumference levels (tertiles); all means are adjusted for age (years), postmenopausal, hormones use. 





























































Figure 13. SQRT HOMA-IR levels by neck circumference and body mass index 
subgroups for women 
!
                                    Body mass index (BMI) kg/m2 
Note: P-interaction represents the p-value for interaction between body mass index (BMI) groups and neck circumference levels (tertiles); 
all means are adjusted for age (years), postmenopausal, hormones use; ** denotes significance post hoc analysis at 0.01 level; *** denotes 
significance at 0.001 level.! 






































Table 14. Multiple binary logistic regression analysis, using each cardiovascular 
disease risk as the dependent variable on neck circumference  





















































































Elevated LDL cholesterol  
 
















Central obesity  
Model 1 























































Model 1: one dependent, one independent (NC) controlling for confounders (age, postmenopausal status, hormone use dietary 
habit & practices, activity level & life style). 
Model 2: one dependent, one independent (NC) controlling for confounders (age, postmenopausal status, hormone use, dietary 
habit & practices, activity level & life style, and BMI) 
Model 3: one dependent, one independent (NC) controlling for confounders (age, postmenopausal status, hormone use, dietary 
habit & practices, activity level & life style, BMI, WC) 
Model 4: one dependent, one independent (NC) controlling for confounders (age, postmenopausal status, and hormone use, 






Figure 14. Multiple binary logistic regression analysis of cardiovascular disease 






















































! OR (95% CI) !
!
Note: OR1: unadjusted, OR2: adjusted for age, menopausal status, and hormonal use, 
eating index, activity index. OR3: adjusted for age, menopausal status, hormonal use, BMI, 
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Figure 14. Multiple binary logistic regression analysis of cardiovascular disease risk factors for 
neck circumference 
Note: OR1: unadjusted, OR2: adjusted for age, menopausal status, and 
hormonal use, eating index, activity index. OR3: adjusted for age, menopausal 
status, hormonal use, BMI, fat%, and WC. 
!
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Table 15. Logistic regression analysis of risk for metabolic syndrome and its 
components by quartile of neck circumference level 
!








    35.0 - 36.5cm 
172 
Q3 
    36.6 - 38cm 
171 
  Q4 
>38cm 
  127 
  All P-trend<0.0001  
Hypertension     
Model 1 1 3.04(1.82-5.09)**   5.55(3.39-  9.08)** 8.76(5.13-14.96)** 
Model 2 1 2.39(1.38-4.12)**   4.77(2.82-  8.07)** 6.76(3.78-12.08)** 
High glucose          
Model 1 1 3.14(1.97-4.99)**   7.81(4.74-12.87)** 15.28(7.95-29.36)** 
Model 2 1 2.47(1.51-4.05)**   6.85(4.05-11.57)** 11.51(5.81-22.77)** 
High Triglycerides     
Model 1 1 1.79(1.11-2.89)*     2.63(1.67-  4.14)** 4.38(2.67-  7.18)** 
Model 2 1 1.57(0.96-2.56)     2.30(1.44-  3.66)** 3.37(2.02-  5.65)** 
Low HDL cholesterol     
Model 1 1 2.17(1.35-3.49)**     2.60(1.64-  4.13)** 3.54(2.08-  6.02)** 
Model 2 1 2.09(1.28-3.42)**     2.36(1.46-  3.81)** 3.28(1.87-  5.75)** 
High LDL cholesterol     
Model 1 1 2.17(1.35-3.49)**     2.60(1.64-  4.13)** 3.54( 2.08-  6.03)** 
Model 2 1 2.09(1.28-3.42)**     2.36(1.46-  3.81)** 3.28( 1.87-  5.75)** 
HOMA-IR  >75th     
Model 1 1 2.98(1.62-5.50)**     3.29(1.83-  5.93)**  3.10( 1.63-  5.84)** 
Model 2 1 2.67(1.44-4.98)**     2.95(1.62-  5.38)** 2.59( 1.34-  5.03)** 
Obesity: BMI≥ 30         
Model 1 1 2.58(1.62-4.09)**     4.78(2.97-  7.67)** 6.34( 3.65-11.01)** 
Model 2 1 2.68(1.67-4.31)**     4.83(2.97-  7.88)** 6.57( 3.69-11.70)** 
Central-obesity: WC ≥ 92     
Model 1 1 5.37(3.25-8.85)** 10.07(5.89-17.23)** 27.01(11.87-61.46)** 
Model 2 1 4.86(2.92-8.12)**   9.07(5.25-15.67)** 23.12(10.00-53.46)** 
Having two risks or more     
Model 1 1 3.66(2.27-5.90)**    9.35(5.48-15.98)            17.13( 8.38-34.99)** 
Model 2 1 2.89(1.74-4.79)**   7.65(4.38-13.38)** 12.57( 5.67-26.47)** 
Metabolic Syndrome 
(harmonized)      
Model 1 1 3.84(2.38-6.20)** 9.82(5.74-16.80)** 17.98(8.79-36.78)** 
Model 2 1 3.06(1.84-5.08)** 8.13(4.64-14.22)** 13.39(6.35-28.23)** 
Metabolic Syndrome (IDF)     
Model 1 1 4.14(2.56-6.69)** 10.58(6.18-18.13)** 19.38(9.47-39.67)** 
Model 2 1 3.30(1.98-5.49)** 8.83(5.04-15.49)** 14.55(6.89-30.72)** 
Model 1: Unadjusted. Model 1:  Adjusted for age, postmenopausal status, hormone use dietary habit & practices, 





Figure 15. ROC curve for neck circumference to predict the presence of three or 
more metabolic syndrome risk factors based on IDF definition in women  
 
! Neck circumference cutoff (NC= 35.5cm), with distance in ROC curve=0.327; Youden 
Index= 0.450, sensitivity= 78.7%; specificity= 66.3%; and accuracy= 75% in 
predicting the presence of risk factors. 
" Neck circumference cutoff (NC= 35cm), with shortest distance on the ROC curve 
from perfect predictor (0.323). 
# Neck circumference cutoff (NC= 36cm), with highest Youden Index, maximum 





































False positive rate (1 - Specificity)
AUC  (95% CI)
0.796 (0.757-0.836); P< 0.001 
!
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Figure 16. ROC curve for waist circumference to predict the presence of two or 
more metabolic syndrome risk factors based on IDF definition in women 
!
! Waist circumference cutoff (WC=92cm) with shortest distance on the ROC 
curve=0.434; Youden Index= 0.318, sensitivity= 78.1%; specificity= 53.7%; and 
accuracy= 70.7% in predicting the presence of risk factors. This cutoff has higher 
sensitivity. 
" Waist circumference cutoff (WC=95cm) with highest Youden Index, maximum 































False positive rate (1 - Specificity)
AUC (95% CI)   
0.711(0.667-0.756); P< 0.001 
!
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Figure 17. ROC curve for body mass index to predict the presence of three or 
more metabolic syndrome risk factors based on IDF definition in women 
 
! Body mass index cutoff (BMI=27.7kg/m2) with shortest distance on the ROC curve 





























False positive rate (1 - Specificity)
AUC  (95% CI)
0.659 (0.612-0.706); P< 0.001 
!
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Figure 18. ROC curve for body fat percentage to predict the presence of three or 














































False positive rate (1 - Specificity)
AUC  (95% CI)
0.587 (0.532-0.642); P< 0.05 
!
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Table 16. Sensitivity, specificity, Youden Index, and distance in receiving operating characteristic (R
O
C
) curve for neck 
circum












































































































































































































































































































































































































































































































































































































etabolic risk factors w
ere defined according to IDF definition (21): elevated triglycerides, ≥ 150 m
g/dL or specific treatm
ent for hypertriglyceridem
ia; reduced HDL 
cholesterol, < 40 m
g/dL for m
en and <50 m
g/dL for w
om
en or specific treatm
ent for this lipid abnorm
ality; elevated blood pressure, systolic blood pressure ≥ 130 m
m
Hg, 
diastolic blood pressure ≥85 m
m
Hg or treatm
ent for previously diagnosed hypertension; elevated fasting plasm
a glucose ≥ 100 m
g/dL or previously diagnosed type 2 
diabetes. Youden Index= TPF-FPF= Sensitivity+ Specificity -1. Distance in RO
C curve = square root of (1-TPF) 2+ FPF
2=(1-sensetivity) 2+ (1-specificty)  2!
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Table 17. Sensitivity, specificity, Youden Index, and distance in receiving operating characteristic (R
O
C
) curve for w
aist 
circum

























































































































































































































































































































































































































































































































































DL cholesterol, < 40 m
g/dL for m
en and <50 m
g/dL for w
om
en or specific treatm
ent for this lipid abnorm
ality; 
elevated blood pressure, systolic blood pressure ≥ 130 m
m
H




ent for previously diagnosed 
hypertension; elevated fasting plasm
a glucose ≥ 100 m
g/dL or previously diagnosed type 2 diabetes. Youden Index= TPF-FPF= Sensitivity+ 
Specificity -1. Distance in RO
C









Table 18. Sensitivity, specificity, Youden Index, and distance in receiving operating characteristic (R
O
C
) curve for body 
m


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DL cholesterol, < 40 m
g/dL for m
en and <50 m
g/dL for w
om
en or specific treatm
ent for this lipid abnorm
ality; 
elevated blood pressure, systolic blood pressure ≥ 130 m
m
H




ent for previously diagnosed 
hypertension; elevated fasting plasm
a glucose ≥ 100 m
g/dL or previously diagnosed type 2 diabetes. Youden Index= TPF-FPF= Sensitivity+ 
Specificity -1. Distance in RO
C









 Table 19. The prevalence of the m
etabolic syndrom
e and central obesity am
ong adult’s Saudi w
om












































e defined as per (IDF, NHLBI, AHA, IAS, IASO
) harm
onized definition guidelines (73); the presence of any three or m
ore of the risk 
factors. ¤M
etabolic syndrom
e defined as per IDF definition guidelines (38); the presence of abdom
inal obesity and tw
o or m
ore of the risk factors. 
M
etabolic risks defined according to IDF criteria (38): central obesity, w
aist circum
ference ≥ 80 cm
 for w
om
en; raised triglycerides (≥1·7 m
m
ol/L); reduced 
HDL cholesterol (<1·03 m
m
ol/L for m




en or specific treatm
ent for this lipid abnorm
ality); raised fasting plasm
a glucose (≥5·6 
m
m
ol/L or previously diagnosed type 2 diabetes); raised blood pressure (systolic BP ≥ 130 m
m
Hg, diastolic BP≥ 85) or treatm
ent for previously diagnosed 
hypertension. IDF W
aist circum













 Table 20. C
om
parison of the prevalence of m
etabolic syndrom








 < 35.5 
N
C







eans ± SD) 
33.1(32.8-33.3) 






































ference. Categorical data w
ere described as n (%
), and continuous data w
ere described as m
eans ± 
standard deviation. ***p-values = 0.000 betw
een the groups of the above and below











e according to joint classification of neck circum
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Chapter 4: Discussion   
Obesity is steadily increasing in the Middle East, especially in Saudi Arabia, and 
is currently one of the most serious health problems in the region. Because of the 
comorbidity associated with obesity, early diagnosis is crucial for more effective 
intervention. The most widely used index of excess body fat is the body mass index 
(BMI). However, several studies have shown that regional (upper body) adiposity is a 
more serious clinical entity than total body fatness. BMI is a poor indicator of central 
adiposity (18). Therefore, other anthropometric measures of upper body adiposity have 
been pronounced. To our knowledge, this is the first study designed to address the 
association between neck circumference and cardiometabolic risk factors in Saudi adults.  
In this cross-sectional analysis of 700 adults aged 18-70 years, the association 
between body composition indices: body fat percentage, body mass index (BMI), neck 
circumference, and waist circumference (WC), as well as, cardiometabolic risk factors 
were examined. First, neck circumference is associated with waist circumference in men 
and women. Second, in women, neck circumference is associated with cardiometabolic 
risk factors beyond the other anthropometric indices. Third, neck circumference 
independently contributes to the prediction of cardiometabolic risk. Fourth, for women 
the body mass index, waist circumference, and neck circumference of ≥ 27.7 Kg/m2, 92 
cm, and ≥ 35.5 cm, respectively, were the best cutoff points to determine subjects with 
metabolic syndrome. Finally, no synergistic effect between NC and BMI or WC on 
metabolic syndrome was observed. 
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Neck circumference and the other indices: The age-adjusted neck circumference 
measurements were significantly associated with BMI (total adiposity index) as well as 
WC, which is frequently used as a surrogate marker of abdominal or upper-body 
(subcutaneous and visceral) fat mass (50, 51). The results show a strong positive 
correlation of neck circumference with BMI and WC in both men and women subjects. 
This was in line with several studies that have examined the association of conventional 
anthropometric measures of adiposity with neck circumference (20, 153, 154).  Onat et 
al. and Hingorjo et al. reported strong correlations of neck circumference with BMI and 
WC (r > 0.6) (21, 150). Stabe et al. found that neck circumference is associated with the 
intra-abdominal (visceral) fat (27). However, BMI and WC are age and sex dependent 
when they are used as indicators of body fatness (108). ). Most importantly, our study 
was controlled for age and all analyses were sex specific. Furthermore, as in Yang et al.’s 
study (147), our results showed a positive association between neck circumference and 
increase of WC in all BMI levels in women, but not in men. Klein et al. stated that the 
cutoff points of WC > 40 in (102 cm) in men and > 35 in (88 cm) in women are derived 
from a regression curve that identified the WC values associated with obesity (BMI > 30) 
(17).  This explains our finding that WC has higher correlations with BMI and body fat 
percentage compared to neck circumference, which is in line with finding from a recent 
study in overweight and obese adults by Joshipura et al (197). The finding from this study 
implied that the incremental added value of using neck circumference would be higher as 
neck circumference would be more independent of BMI compared to waist 
circumference (197). This may also be applied to the body fat percentage in our study. 
We used a DEXA scan as a gold standard for the assessment of body fat percentage, 
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however, the DEXA dose not quantify the vascular and subcutaneous fat, especially in 
morbid obese (198). Computed tomography (CT) and magnetic resonance imaging (MRI) 
are considered the gold standard for detailed assessment of upper body fat sections (199, 
200). 
Anthropometric measurements are the most basic assessment tools with a well- 
established relationship with body fat distribution and metabolic complications that 
overcome the expense and availability limitations of the gold-standard methods (e.g., CT, 
MRI) in clinical practice (199, 200). Neck circumference measurement requires less 
effort for both the examiner and the subject than other anthropometric methods. It 
requires a single measurement site with less bias of anatomical and observer variations 
(27). In addition, the measurement of neck circumference may be more socially 
acceptable, convenient, and tolerable, especially for overweight and obese women (153, 
154, 201). Neck circumference is measured directly at the body surface, which is more 
stable than the surface used for the measurement of WC or HC because light clothing 
may make the measurement challenging. Thus, the use of WC or HC may increase the 
chance of getting false results due to researcher or subjects' effect (201). Neck 
circumference provides good inter- and intra-observer reliability (202). On the other 
hand, the risk prediction of WC is influenced by the anatomic location of measurement, 
especially in women. Comparison of WC values is complicated by the absence of 
generally accepted anatomic landmarks for measuring the WC in different clinical 
studies: the midpoint between the last intercostal arch and iliac crest; the upper border of 
the iliac crest; the narrowest circumference abdomen; and distance above the umbilicus. 
Whereas, each specific site used to measure the WC influences the obtained WC value, 
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which can limit the evaluation of body fat distribution and their corresponding metabolic 
risks, especially in women (17, 25, 26, 27). The cutoff values of WC for overweight and 
obesity vary widely throughout the world. WC may also be biased by the absence of 
specific, standardized cutoff points for some populations, including those of the Arabian 
Gulf region.  
Measuring neck circumference is a straight-forward process with minimal cost 
and time requirements (154, 196). As a result, neck circumference measurement provides 
a better and potentially more accurate clinical screening tool for predicting obesity and 
metabolic syndrome.  
Neck circumference and the cardiometabolic risk factors: General obesity (designated 
by BMI) and regional adiposity (designated by WC or NC) have been related to elevated 
risk for metabolic and cardiovascular diseases (16, 50, 108). Few studies have examined 
the relationship between neck circumference and cardiometabolic risk factors in adults 
and, at the same time, examined the association of other anthropometric indices (BMI, 
WC, WHR, or body fat percentage). Zhou et al. study (152), in southern China, has 
implemented a similar analysis performed in this study (Table 11). Their study showed 
that neck circumference is associated with elevated SBP, DBP, triglycerides, fasting 
glucose, insulin, IR, and reduced HDL. Our findings are consistent with associations 
detected in that study. However, they found that the associations were higher between 
BMI and WC with the cardiometabolic risks than with neck circumference. In contrast, 
we found that neck circumference has the highest association with the cardiometabolic 
risks. The correlation in their study was not gender specific, which may imply that the 
observed disagreement is due to gender differences. Moreover, that study was among 
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Chinese adults with normal weight (mean BMI= 22.67±3.1) and with no previously 
prescribed medication for hypertension, diabetes, or dyslipidemia. Thus, that study is 
different from our study, in which they included only healthy adults with no obesity-
induced health problems (152). The data from San Juan Overweight Adults Longitudinal 
Study (SOALS), which recruited overweight or obese adults who were free of previously 
diagnosed diabetes, has shown consistent results to our study (197). Neck circumference 
revealed higher positive associations with prediabetes and lipid abnormality than BMI, 
WC, and body fat percentage. 
Nevertheless, the association of neck circumference with cardiometabolic risk 
factors has been conducted in several studies. The results of the present study 
demonstrated a clear and consistent positive association of neck circumference 
measurement with elevated SBP, DBP, triglycerides, fasting glucose, insulin, and IR in 
women. These associations were present on both univariate and multivariate analyses and 
remained highly significant after the adjustment for various demographic, lifestyle, and 
medical characteristics. These findings are in line with numerous studies (18, 22, 155). 
Brazilian women’s neck circumferences showed an association with hypertension, insulin 
insensitivity, hypertriglyceridemia, lower HDLc, and higher fasting glucose level. In 
addition, neck circumference and WC measurements shared significant and independent 
predictions of IR and metabolic syndrome risks and neck circumference was a better risk 
indicator for women than for men (27). This deferential effect of neck circumference by 
sex has also been reported in other studies (18, 22). On the contrary, the contribution of 
neck circumference in predicting metabolic syndrome was stronger in men compared to 
women in the Turkish population (21). Although gender differences exist in these studies, 
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neck circumference was significantly associated with cardiometabolic risks. And after 
further control for the other anthropometric indices, neck circumference was positively 
associated with each component of metabolic syndrome except for low HDLc (18). Our 
findings are in agreement with these studies in which the neck circumference was related 
to cardiovascular risk factors independent of body fat percentage, WC, and BMI (27, 155, 
156). In a longitudinal cohort study of 364 subjects, Ben-Noun and Laor reported that 
changes in the neck circumference did not affect HDLc levels after the adjustment for 
WC (148). Another previous study reported that neck circumference is correlated with 
triglycerides and reduced HDLc beyond BMI and waist circumference (203). The 
Framingham Heart Study demonstrated that the neck circumference is associated with IR, 
hypertension, and dyslipidemia, independent of vascular adiposity (18). Neck 
circumference was also an associated factor for Type 2 diabetes after the control for BMI 
and waist circumference (170). Likewise, neck circumference has been associated with 
hypertension after adjustment for BMI (204).  
A recent study observed a significant association of neck circumference with 
indicators of chronic kidney disease [the Cockcroft-Gault formula (eGFRCG), 24-hour 
urine creatinine clearance rate (24 hr CCR), uric acid, and urine microalbuminuria] and 
with the traditional cardiovascular risk factors [High-sensitivity C-reactive protein 
(hsCRP), triglycerides, LDLc, and HDLc] (204). Neck circumference also correlated 
significantly with intima-media thickness of common or internal carotid arteries, which is 
a direct measure of subclinical atherosclerosis, independent of BMI and WC (205). In a 
Brazilian study that included 43 obese adults, neck circumference demonstrated a strong 
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relationship with Plasminogen Activator Inhibitor (PAI-1), which is an adipokines related 
to hyperthrombotic state, inflammatory state, and cardiovascular diseases (206).  
Our data and results from other studies suggest that neck circumference 
contributes to the cardiometabolic adverse consequence as an upper body fat marker (18, 
21, 27, 155, 156). Upper body subcutaneous fat, as measured by neck circumference, 
may confer risk beyond vascular adiposity (18, 152). The precise mechanism of neck 
circumference in the prediction of metabolic problems is not well understood. However, 
changes in regional fat distribution, including subcutaneous fat of the neck, are associated 
with adipose tissue dysfunction and abnormal adipokine secretion leading to metabolic 
diseases (21, 22). Upper body fat is more lipolytically active than lower body adipose 
tissue, which may be another mechanism to explain the association of neck 
circumference with cardiometabolic risk. Upper body subcutaneous fat is responsible for 
a much larger proportion of systemic free fatty acid release than visceral fat, specifically 
in obese individuals (19, 85). This lipolytic activity of upper body fat and high levels of 
plasma free fatty acids could result in insulin resistance (85), increased VLDL-
triglyceride production (158), oxidative stress (167), and the development of 
hypertension. Therefore, neck circumference, as representative of upper body fat, should 
be able to predict the metabolic and cardiovascular risk (18, 27, 156, 157, 197, 207, 208)  
Prediction of cardiometabolic risks: In our study, adjustment for various 
metabolic risk factors, such as age, sex, menopausal status, hormonal use, lifestyle, BMI, 
and WC, did not change the associations between neck circumference and 
cardiometabolic risks, suggesting that the effects of larger neck circumference for women 
are less likely to be mediated by these factors. The regression procedure indicated that the 
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enlargement of neck circumference increases the risk of developing IR, 
hypertriglyceridemia, hypertension, central obesity, metabolic syndrome, and 
hyperglycemia by 1.2; 1.2; 1.3; 1.5; 1.6; and 1.7 times, respectively. Several studies have 
demonstrated similar results, in which, even after they control for BMI and WC, neck 
circumference presented significant prediction of metabolic syndrome components by 1.3 
to 1.9 times (18, 150). In our study, women in the fourth quintile (NC >38) are associated 
with an increased OR of all metabolic syndrome components. We observed an extremely 
elevated risk, as much as 23-fold, 13-fold, and 11-fold, in central obesity, metabolic 
syndrome, and hyperglycemia, respectively. In addition, Laakso et al. reported that 
women with neck circumference in the highest quintile were associated with about a 
fivefold increased risk of elevated fasting glucose and a threefold increased OR of 
hypertension after adjustment for BMI (100). Other studies established that neck 
circumference in the highest quartile added sevenfold, eightfold, or 17 fold risks to the 
IR, metabolic syndrome, and obesity compared with that in the lowest quartile (197).  
Importantly, a significant synergistic effect between neck circumference and 
visceral adipose tissue on cardiometabolic risk factors was established in the Framingham 
Heart Study (18). The present study is the first to examine the synergistic effect between 
neck circumference and BMI or WC on metabolic syndrome.  Our study reported the 
absence of synergistic effect between neck circumference and other obesity indices on 
metabolic syndrome. The findings of our study and the Framingham Heart Study (18) 
suggest that neck circumference, as a proxy of upper-body section fat, would be helpful 




Neck circumference cutoff points: The overall performance of neck 
circumference, area under curve AUC (0.796), in predicting metabolic syndrome using 
the IDF criteria was better than other anthropometric indices: WC (0.667); BMI (0.659); 
and body fat percentage (0.587). Few studies have compared the prediction power of 
neck circumference with other anthropometric indices. Yan et al. found that neck 
circumference and WC shared the same predictive power AUC (NC=0.73, WC=0.74) in 
women (156). However, in Zhou et al.’s study, neck circumference had a significantly 
large AUC (0.703), but was relatively lower than those of WHR (0.766); WC (0.764); 
and BMI (0.723) (152).   
For women, the optimal cutoff point to predict metabolic syndrome was 35.5 cm. 
The optimal cutoff point was within the range of 33-36 cm reported in the literature of 
neck studies (21, 27, 147, 151, 152, 155, 156, 157). Some studies considered NC =35 cm 
as the optimal cutoff value for the prediction of the development of metabolic syndrome 
(21, 145, 156) 
We suggest that the WC value of 92 cm would be more appropriate for defining 
central obesity and predicting the presence of two or more metabolic risk factors in Saudi 
women. This value differs from the recommended thresholds for American (88 cm) and 
European (80 cm) women by 4 and 12 cm, respectively (38). However, our finding 
concurs with the results from previous studies in the Arabian Gulf region on determining 
the optimal waist circumference cutoff for metabolic syndrome in Qatari and Iranian 
women (127, 129). Other studies showed that optimal WC cutoff points are 84.5 cm for 
Omani women, and 99 cm for Iraqi women (126, 128).  
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Differences in the definitions of metabolic syndrome and in body sizes could 
explain the discrepancies in the optimal cutoffs of neck circumference and WC among 
different populations. As a result, ethnic specific cutoff values of neck circumference and 
WC are required for the prediction of cardiometabolic abnormalities (152,157, 210). 
Neck circumference is an excellent independent cardiometabolic predictor that 
exceeds other anthropometric indices in this study of Saudi women. However, WC, BMI, 
and body fat percentage denoted lower prediction power. WC could underestimate the 
real cardiovascular risk in subjects with small stature, which may be important in many 
populations, such as our Saudi sample (211, 212). Another reason might be from the 
different settings of studied populations, as our study included subjects in their late 
middle ages to older adults since our inclusion criteria was for subjects who were 18-70 
years old (156, 157). For individuals with a BMI ≥ 35, waist circumference adds little to 
the predictive power of the disease risk classification of BMI (130). Aging women tend 
to gain weight and have less estrogen protecting them against cardiovascular diseases 
(213). Fat distribution changes with aging and women develop a more central distribution 
(android shape) that has been related to cardiometabolic abnormalities (214).  
These findings imply that associations between WC and cardiometabolic risks 
might be mediated by obesity (BMI, body fat percentage) in our sample. Consequently, 
ethnic-specific cutoff points of neck circumference should be required for the prediction 
of metabolic syndrome (147, 152, 156), particularly for Saudi women.  
Lastly, although neck circumference shows a strong association with both central 
obesity and metabolic syndrome, the consideration of neck circumference as a screening 
test is a reasonable approach. Women with NC < 35.5 cm do not require additional 
!
! 107!
evaluation. Women with a neck circumference above this level require a more 
comprehensive evaluation of their metabolic and cardiovascular risk. 
Strength and limitations of the study: To our knowledge, this is the first study to 
determine cutoff values of neck circumference for Saudi women that identify overweight 
and obesity and its associated cardiometabolic risk factors. These data add to the current 
literature by showing that neck circumference is an independent predictor of obesity and 
metabolic syndrome after adjusting for other anthropometric indices. In this study, the 
effects of all possible confounders were assessed. In this study, DEXA scan was used to 
quantify total body fat percentages.  However, other methods, such as CT scan, could 
quantify upper body fat much better. In addition, the cross-sectional nature of this study 
prevents firm causal conclusions. This study was conducted in one city, limiting the 
generalization of our findings to all Saudi women. However, given the significant and 
consistent associations detected in our study and the similar findings from different 
populations in other studies, neck circumference shows promise as an alternative marker 
for the metabolic and cardiovascular risks associated with central or visceral adiposity. In 
addition to medical-center-based, community-based, prospective research is needed to 
evaluate whether neck circumference is an important risk factor for the development of 





The current study shows that neck circumference is associated with other 
anthropometric measurements in men and women. In Saudi women, neck circumference 
is an independent predictor for metabolic and cardiovascular risks above and beyond the 
body mass index and waist circumference. Our results indicated that the appropriate neck 
circumference to predict three or more metabolic risk factors in Saudi women is 35.5 cm. 
In addition, the appropriate waist circumference to predict two or more metabolic risk 
factors is 92 cm. The prevalence of central obesity and metabolic syndrome was reduced 
among women according to this waist circumference cutoff. Metabolic syndrome, 
obesity, and central obesity are more prevalent in women with a neck circumference 
≥35.5 cm. 
The current study will contribute not only to the understanding of the importance 
of the appropriate assessment of upper body obesity in screening metabolic syndrome but 
also to the providing of practical guidance in identifying individuals with metabolic 
syndrome. This work is aimed to contribute to the establishment of proper procedures for 
the prevention or delay in the development of diabetes and/or cardiovascular disease. 
To our knowledge, this is the first study to investigate the appropriate neck 
circumference cutoff for the diagnosis of upper body obesity and metabolic syndrome in 
the entire Arabian Gulf region. However, our results are not applicable to all Arab 
women. The findings of the present study are derived from a sample of adult Saudi 
women in Riyadh city and are applicable to this population.








أفضل الطرق لتقيم زيادة الوزن بجمع معلومات حول  أقوم أناحالياً  . باحثة  <..........> أناالسالم عليكم، 
 تسهم سوف و إلى المشاركة في مشروع بحثي هذا كتدعو أود .الدكتوراهكمتطلب لرسالة  والسمنة عند السعوديون
الالزمة لتحديد نسبة انتشار السمنة بدقة، تحسين برامج العالج، ومحاربة  مالتقيي رمعاييفي تحديد  ةالمشارك هذه
 ةانتشار السمنتقلل  أننها ئمن شامعلومات مفيدة  الدراسة هذهتقدم  لنا ، سوف بمشاركتك .السمنة في السعودية
 .جمعأالجانبية ليس في السعودية فحسب بل في دول الخليج العربي  وأعراضها
سرية المعلومات التي سوف نحصل عليها منك أو من  سوف نبذل قصارى جهدنا للحفاظ على أنناأؤكد  وأود أن
كما أؤكد لك أيضا أنه لن  .المعلومات في ملف سري خاص  بهذهكما أننا سوف نحتفظ  ,خالل الملف الخاص بك  
في  ومشرفي الدراسي بك في االستبيان ولن يطلع  عليها أحد سوى أنا متعلقةاسمك أو أي معلومات شخصية يكتب 
 .المتحدة األمريكية الواليات
ممارستك  ية،ئالغذاسلوكياتك  ،تاريخ حالتك الصحيةسوف أقوم به هو أن أطرح عليك بعض األسئلة حول  كل ما
ممرضة العيادة سوف تأخذ , لطبيبوكذلك  خالل التحضيرات السابقة لدخولك لنمط حياتك المعيشي ، , للرياضة 
وحرصنا أن تكون من نفس جنس المشارك ( الطول، الوزن، محيط الرقبة، و محيط الخصر)قياساتك الجسمية 
 DEXA نستخدم جهاز  إذا أذنت لي بذلك ، سوف .دقائق 01الي  5وسوف يستغرق   .لتفادي حدوث أي حرج
 قسم زيارة منك يطلب سوف ، الطبيب زيارة من االنتهاء بعد  .وكمية الكتلة العضلية الجسم في الدهون لقياس
حيث . احد و أسبوع غضون في العيادة نفس في المختبر إلى أخرى زيارة بجدولة نقوم سوف النتائج المخبرية،
 سوف يطلب منك ذلك وبعد ت الالزمة، سيشرح لك اإلجراء المتمكن فني األشعة .المركز نفس في األشعةيلزمك 
وسيستغرق مسح الجهاز  .جسمك على (DEXA)الجهاز من السينية األشعة عرض وسيتم، السرير على االستلقاء
من الملف الطبي ( أسبوعين)أحتاج أيضا إلى تسجيل بعض النتائج المخبرية الحديثة. دقائق 01-5 لجسمك حوالي
ساعه وبعد ذلك؛ فني المختبر سوف يشرح لك 01-01الحضور صائم لمدة في حال عدم توفر  الخاص بك
كمية  .اإلجراءات الالزمة، و بعدها سيطلب منك الجلوس و سيتم سحب الدم من الوريد في ذراعك باستخدام إبرة 
أي ألم إذا كان هناك صعوبة في إيجاد الوريد سيتم استبعادك لتجنب  (. حوالي نصف ملعقة) مل6الدم المطلوب هي 
 . ال لزوم له
قررت عدم  إذا عدم المشاركة وفي  هذا البحث هو عمل تطوعي بحت كما أن لك كامل الحق مشاركتكم في
وعلى الخدمات  حقوقك ولن يؤثر ذلك على عقوبة التوقف في أي وقت دون أي ، يمكنك في هذا البحث المشاركة
 .العيادة لك (تقدمها ) التي توفرها
 هذا عن ناجمة إصابات عن اإلبالغ تريد أو في بحث علمي كمشارك حقوقك حول سؤالأي  لديك كان إذا
 : االتصال الرجاء البحث،
 : 1660-515-110 هاتف
 : irb@umd.edu اإللكتروني البريد
:أو يمكنكم المراسلة على العنوان التالي  
University of Maryland College Park  
Institutional Review Board Office 
4021 Marie Mount Hall 
College Park, Maryland, 02710 








 بارك،ج كول ميريالند، جامعةب( IRB)لمجلس المراجعة المؤسسي  وفقا البحث هذا تقييم ت مراجعة وتم' وأخيرا
 اللفظي طلب المشاركة سمعت ،سنة 00 عن قلت ال أنك إلى يشير اللفظي قبولك .الجنة المختصة بأبحاث اإلنسان
 الدراسة هذه في المشاركة على طوعا توافق كوأن ,بشكل مرضى و وافي كأسئلت كل على اإلجابة تم ،(لك قرأت)
 .البحثية
 .شكرا لوقتكم الكريم: ال اإلجابةكانت  إذا
 الحوار أكمل :نعم اإلجابةكانت  إذا 
 ؟اآلنستغرق بضع دقائق، هل لديك الوقت ستي توال األسئلةاطرح عليك بعض  أن أودقبل المشاركة، 
 .قابلةحدد وقت آخر إلجراء الم: ال اإلجابةكانت  إذا
 الحوار أكمل: نعم اإلجابةكانت  إذا
Screening Questionnaire 
 
Interviewer _________________________________ Date 
______/______/______ 
Participant ID Number __________________________________ 
 عام؟ 61- 00هل عمرك بين  (0
A. نعم 
B. ال 
 سعودي الجنسية؟ أنتهل  (1
A. نعم 
B. ال 
 تشكو من السرطان؟ أو، لعضوءتمت لك زراعة  أو، األعضاءهل تعاني من فشل في  (1
A. ال 
B. نعم 
 رقية؟دهل سبق و شخصك الطبيب بتضخم الغدة ال (5
A. ال 
B. نعم 
 :للنساء فقط 
 حامل ؟ أنتيهل  (5
A. ال 
B. نعم 
 هل ترضعين رضاعة طبيعية في الفترة الحالية؟ (6
A. ال 
B. نعم 
 .ال( 6ـ1)األسئلةوالثاني نعم، وبقية  األول ينالسؤال إجابةتكون  أنيتوجب  
يعتبر غير : أكثر أوعن سؤال  اإلجابةرفض المشارك  أو B األسئلةمن  إجابة أي في حال كان خيار 
 . مستحق للمشاركة في الدراسة أومؤهل 
  








o  شروط المشاركة غير مستوفية في  لألسفاشكر مبادرتك للمشاركة، ولكن ”.مستحق للمشاركة أوغير مؤهل
 ”.حالتك
o  كل اآلجاباتA  :“اشرح لك بعض تفاصيل المشاركة أنوأود . مؤهل للمشاركة معنا أنت.   ” 
اسم )مركزـــــــــــــــــــــــــــــنفس هذا الالدراسة يستوجب لقاء واحد في  هذهكما سبق وذكرت، المشاركة في 
 -(المركز الصحي
 
أطرح عليك دقيقة،  05ونجري معك حوار لمدة . أخرىسوف نخبرك بما لك من حقوق مرة  نبداء بالمقابلةعندما 
 وكذلك ، نمط حياتك المعيشي, ستك للرياضة ممار ية،ئالغذاسلوكياتك  ،تاريخ حالتك الصحيةبعض األسئلة حول 
الطول، الوزن، محيط )قياساتك الجسمية  تأخذسوف  ممرضة العيادة, خالل التحضيرات السابقة لدخولك للطبيب
 إلي 5ويستغرق ذلك . حرج أيمن نفس جنس المشارك لتفادي حدوث  تكون أنوحرصنا ( الرقبة، و محيط الخصر
وفي نهاية الزيارة ستحصل علي . مالبس خفيفة وان تكون عاري الرأس و حافي القدمين ترتدي أنويجب , دقائق 01
 .ملخص قياساتك الجسمية
 
غرفة معزولة هنا في نفس المركز وذلك لمزيد من قد جهزنا , دقيقة 01-5ولمدة  اآلن المقابلة إجراءهل يمكننا "
 الخصوصية
 "هيا بنا لنبدأ الحوار, اشكر تعاونكم :إذا كانت اإلجابة نعم
 .حدد وقت آخر إلجراء المقابلة: إذا كانت اإلجابة ال
 (الموعد في الجدول ادناة إدخال ءالرجا. )لنحدد تاريخ  موعد قدومك للعيادة 




 استفسار؟ أوسؤال  أيهل لديك  





Visit #A Appointment (51mn) 
 
Day:  Mon    Tue    Wed    Thu    Fri   Sat 
Date:  _____/_____/_______ 
Time:  __________ to __________ 
Appendix 1B 
 
Obesity Assessment Study – Screening tool (English) 1"/"4"
 
Reem "AlBassam " "
File number should not be on survey with serial number; when is serial # assigned? Participant serial # 
__________ 
 
“Hello, my name is < Reem Al-bassam >. I am, a PhD student at the 
University of Maryland in the United States of America. I’m collecting data about 
the best way of assessing overweight and obesity in Saudi people as a 
Doctor’s dissertation requirement. I am inviting you to participate in this project 
since your valued participant will aid us to find standardized assessment tools to 
determine accurate prevalence, treatment protocols, and achieve control of 
obesity among Saudi population.  By participation, findings of this study will 
contribute to the prevention of the epidemic of obesity and its complications in 
Saudi Arabia and the entire Arabian Gulf. 
In our study, we guarantee the confidentiality of the collected information that 
we will get from you or through your file, and we will keep this information in a 
confidential file. Also I assure you that we will not write your names or any other 
information that can directly be linked to you. Only the file number will be 
obtained and linked to serial number to be used in the event if there is any 
missing data. Only my advisor in United States (Dr. David K. Y. Lei) and I (Reem 
AlBassam) will have access to the data through password protection.  
All I need is to ask some question related to your socio-demographic data, 
medical history, dietary habit and practices, as well as your physical activity and 
lifestyle. Also, if you authorized me to do so, I will obtain some recent laboratory 
results of your medical record. If your medical record does not have required 
biochemical parameters, we will schedule you for another visit to the laboratory in 
the same clinic within one week. Prior to seeing your doctor and during the 
routine preparation session, some extra measurements other than height (cm), 
weight (kg) will be taken for you, with estimated time of 5-10 minutes in order to 
be completed. These include: neck circumference (cm), waist circumference 
(cm). Finally, after completing the doctor visit, you will be asked to visit the 
radiology department within the same center and do a DEXA X-ray, with 
estimated time of 15-20 minutes in order to be completed. 
Your participation in this research is completely voluntary.  You may choose 
not to take part at all.  If you decide to participate in this research, you may stop 
participating at any time.  If you decide not to participate in this study or if you 
stop participating at any time, you will not be penalized or lose any benefits to 






Obesity Assessment Study – Screening tool (English) 2"/"4"
 
Reem "AlBassam " "
File number should not be on survey with serial number; when is serial # assigned? Participant serial # 
__________ 
 
If you have questions about your rights as a research participant or wish to report 
a research-related injury, please contact:  
 
University of Maryland College Park  
Institutional Review Board Office 
1204 Marie Mount Hall 
College Park, Maryland, 20742  
 E-mail: irb@umd.edu   
Telephone: 301-405-0678 
Finally’ this research has been reviewed according to the University of Maryland, 
College Park IRB procedures for research involving human subjects. Your written 
acceptance (signature) indicates that you are at least 18 years of age; you have 
read this consent (have had it read to you); your questions have been answered 
to your satisfaction and you voluntarily agree to participate in this research study.  
If NO:   “Ok… not a problem thank you for your time.”   
If OK, complete below. 
“In order to participate, I need to ask you a few questions that will take just a 
minute or so to answer. Do you have a couple of minutes that I can ask these 
questions now?” 
If NO, schedule a better time to screened.   




Obesity Assessment Study – Screening tool (English) 3"/"4"
 
Reem "AlBassam " "




Interviewer _________________________________ Date 
______/______/______ 
Participant ID Number __________________________________ 
1) Are you between 18 to 70 years of age? 
A. Yes  
B. No. 
2) Are you Saudi? 
A. Yes  
B. No. 
3) Have you had Organ Failure, Transplant, or Cancer? 
A. No  
B. Yes 
4) Have you been diagnosed with a thyroid nodule? 
A. No  
B. Yes 
For females only 
5) Are you pregnant or do you think you may be pregnant before the clinic 
visit? 
A. No  
B. Yes 
6) Are you nursing or lactating? 
A. No  
B. Yes 
First and second questions must be YES; the followed (3-6) must be NO.  
If ANY question has the choice  “B” or the individual declines to complete one or 
more questions:  Check box for ineligible. 
o Ineligible. “Thank you for your interest in the study, but unfortunately you do not 
qualify for this study.” 
o If NO FLAGS for exclusion:  “You seem to be a good candidate for this study.  Let 
me tell you more about it.” 
“As I mentioned, participants in the study will be measured 1-2 times here at the 
same Primary heath center name: _________________].  
Appendix 1B 
 
Obesity Assessment Study – Screening tool (English) 4"/"4"
 
Reem "AlBassam " "
File number should not be on survey with serial number; when is serial # assigned? Participant serial # 
__________ 
 
“The time we start our meeting, we will go over the written consent. We will ask 
some question related to your socio-demographic data, medical history, dietary 
habit and practices, as well as your physical activity and lifestyle. Also, if you 
authorized me to do so, I will obtain some recent laboratory results of your 
medical record. If your medical record does not have required biochemical 
parameters, we will schedule you for another visit to the laboratory in the same 
clinic within one week. Prior to seeing your doctor and during the routine 
preparation session, some extra measurements other than height (cm), weight 
(kg) will be taken for you, with estimated time of 5-10 minutes in order to be 
completed. These include: neck circumference (cm), waist circumference (cm). 
Finally, after completing the doctor visit, you will be asked to visit the radiology 
department within the same center and do a DEXA X-ray, with estimated time of 
15-20 minutes in order to be completed.” 
“You will receive a full report of your measurements at the completion of this 
visit.” Supporting document # 5 
“Do you have 15 minutes that we can start our interview session now?” 
If Yes, “thank you for your time. We have arranged an empty room within this 
center for the interview for more privacy, lets go there and start our session.” 
If No, schedule a better time to meet. 
Let’s schedule a 30min block for the measurements and the interview during another Visit.  
(Enter visit information in the box below.) 
Mon Tue Wed Thu Fri 
 
Inform the candidate 
! Do you have any questions? 
! I look forward to seeing you at < the interview Visit   appointment time and date>.  End  
 
Visit #1 Appointment (30min) 
 
Day:  Mon    Tue    Wed    Thu    Fri   Sat 
Date:  _____/_____/_______ 




 إقرار بالموافقة على المشاركة بالدراسة البحثية
 
 :إقرار بالموافقة على المشاركة بالدراسة
1/2 
عند سكان مدينة الرياض  وأضرارها الصحية إيجاد معيار قياسي جسمي لتقييم زيادة الوزن والبدانة  عنوان البحث
 .السعوديين البالغين
 الغرض من الدراسة 
الغرض من دراستي هو اختبار قدرة محيط الرقبة على تشخيص زيادة الوزن والسمنة، ارتفاع الدهون واألعراض 
 .  وكذلك نود تحديد قياسات معيارية للجنسين من السعوديون المقيمين في مدينة الرياض. المصاحبة له
شار السمنة بدقة، تحسين برامج العالج، سوف تسهم في تحديد معايير التقييم الالزمة لتحديد نسبة انتومشاركتكم 
معلومات مفيدة من شأنها أن تقلل انتشار  تقدم هذه الدراسة لنا ، سوف بمشاركتك .ومحاربة السمنة في السعودية
 .السمنة وأعراضها الجانبية ليس في السعودية فحسب بل في دول الخليج العربي اجمع
 اإلجراءات المتبعة
بعد أن قرأت ووقعت هذه الموافقة ووافقت على المشاركة ، ستتم المقابلة في غرفة فارغة داخل  :الخطوات المتبعة
 .هذه العيادة  لنوفر لك الراحة
خالل هذه الزيارة سيطلب منك استكمال هذا االستبيان التي تشمل بعض األسئلة حول التاريخ الطبي  :االستبانة
 .وبعض العادات و الممارسات الغذائية الخاص بك وبعائلتك ، مستوى نشاطك البدني ،
ممرضة العيادة سوف تأخذ قياساتك , وكذلك  خالل التحضيرات السابقة لدخولك للطبيب :القياسات الجسمية
وحرصنا أن تكون من نفس جنس المشارك لتفادي حدوث ( الطول، الوزن، محيط الرقبة، و محيط الخصر)الجسمية 
 . دقائق 01إلى  5وسوف يستغرق أخذ القياسات الى  . فة و تكون حافي القدمينيجب أن ترتدي مالبس خفي. أي حرج
بعد االنتهاء من .  لقياس الدهون في الجسم وكمية الكتلة العضلية AXEDإذا أذنت لي بذلك ، سوف نستخدم جهاز  
ح لك اإلجراء ت فني األشعة المتمكن سيشر. زيارة الطبيب ، سوف يطلب منك زيارة قسم األشعة في نفس المركز
( AXED)وسيتم عرض األشعة السينية من الجهاز.  الالزمة، وبعد ذلك سوف يطلب منك االستلقاء على السرير
 . دقائق 01-5وسيستغرق مسح الجهاز لجسمك حوالي . على جسمك
. ي الخاص بكمن الملف الطب( أسبوعين)أحتاج أيضا إلى تسجيل بعض النتائج المخبرية الحديثة: التحاليل المخبرية
في حال عدم توفر النتائج المخبرية، سوف نقوم بجدولة زيارة أخرى إلى المختبر في نفس العيادة في غضون أسبوع 
 .و احد 
 ( :خالل أسبوع واحد)الزيارة الثانية إذا لزم األمر 
ة، و بعدها وبعد ذلك؛ فني المختبر سوف يشرح لك اإلجراءات الالزم. ساعه01-01يلزمك الحضور صائم لمدة 
حوالي )مل 6كمية الدم المطلوب هي . سيطلب منك الجلوس و سيتم سحب الدم من الوريد في ذراعك باستخدام إبرة 
 . إذا كان هناك صعوبة في إيجاد الوريد سيتم استبعادك لتجنب أي ألم ال لزوم له(.  نصف ملعقة
 المخاطر المحتملة والمضايقات
قد تشعر بقليل من االنزعاج أثناء إجراء القياسات الجسمية . مشاركتك بهذا البحث تشمل الحد األدنى من المخاطر  
ممرضة , خالل التحضيرات السابقة لدخولك للطبيب. ولك  حرية القرار حينها بالتوقف  عن المشاركة بهذا البحث
 .فس جنس المشارك لتفادي حدوث أي حرجالعيادة سوف تأخذ قياساتك الجسمية وحرصنا أن تكون من ن
سوف تكون عرضة  لكمية ضئيلة من . بالحد األدنى من احتمالية زيادة المخاطر( AXED)ويرتبط جهاز 
،  وتقارب الكمية التي تتعرض لها عندما تكون تحت أشعة الشمس 1010merm-1010اإلشعاع الضوئي ما يعادل 
،   ولكن يمكن أن يكون (merm01)لجسم خالل أشعة الصدر مثال وهو اقل من ما يتعرضه ا. لمدة خمس ساعات
وسوف نختصر وقت القياسات قدر اإلمكان، و . هناك بعض االنزعاج الطفيف من االستلقاء على نفس  الوضعية
 . كذلك سوف نسمح لك بوقت فاصل إذا لزم األمر
، إذا فقدت الوعي أو شعرت بالدوار أثناء ومع ذلك . سحب الدم يحتمل بعض المضاعفات و تشمل اإلغماء والدوخة 
ثم سوف يطلب منك االستلقاء على . اإلجراء، سنتوقف على الفور، و سوف يطلب منك أن تضع رأسك بين ركبتيك 
وكذلك  . إلى جانب ذلك، إذا كان هناك صعوبة في إيجاد الوريد سيتم استبعادك لتجنب أي ألم ال لزوم له. األرض
األلم أثناء سحب عينية الدم وفي بعض الحاالت  تحصل بعض الكدمات بعد اخذ العينة،  يمكن أن تتعرض لبعض




بالمضادات الحيوية على واالحمرار بالذراع، ولكن في مثل هذه الحالة سوف يطلب منك أن تأتي إلى العيادة للعالج 
 .الفور
رغم عدم وجود فوائد مباشرة، سوف يسهم هذا البحث في تحديد معايير التقييم الالزمة لتحديد نسبة   الفوائد المحتملة 
سوف تقدم هذه الدراسة  بمشاركتك لنا ،. انتشار السمنة بدقة، تحسين برامج العالج، ومحاربة السمنة في السعودية




أننا سوف نبذل قصارى جهدنا للحفاظ على سرية المعلومات التي سوف نحصل عليها منك أو من خالل الملف 
كما أؤكد لك أيضا أنه لن يكتب اسمك . ننا سوف نحتفظ  بهذه المعلومات في ملف سري خاص كما أ,الخاص بك  
أو أي معلومات شخصية متعلقة بك في االستبيان ولن يطلع  عليها أحد سوى أنا ومشرفي الدراسي في الواليات 
 .المتحدة األمريكية
 
مشاركتكم في هذا البحث هو عمل تطوعي بحت كما أن لك كامل الحق في :  الحق في التوقف وعدم المشاركة
التوقف و عدم المشاركة و إذا قررت عدم المشاركة في هذا البحث، يمكنك التوقف في أي وقت دون أي عقوبة 




  حق المشاركة
إذا كان لديك أي سؤال حول حقوقك كمشارك في بحث علمي أو تريد اإلبالغ عن إصابات ناجمة عن هذا البحث، 
 :الرجاء االتصال 
 1660-015-110:  هاتف
 dmu.rud@irbالبريد اإللكتروني 
 :أو يمكنكم المراسلة على العنوان التالي
University of Maryland College Park  
Institutional Review Board Office 
0110 Marie Mount Hall 
College Park, Maryland, 11601 
 بيان الموافقة 
 بجامعة ميريالند، كولج بارك،( BRI)وأخيرا تمت مراجعة و تقييم هذا البحث وفقا لمجلس المراجعة المؤسسي 
، تم (قرأ لك)سنة، قرأت طلب المشاركة  00توقيعك يشير إلى أنك ال تقل عن . الجنة المختصة بأبحاث اإلنسان
 .وأنك توافق طوعا على المشاركة في هذه الدراسة البحثية, اإلجابة على كل أسئلتك بشكل مرضى و وافي
 . إذا كنت توافق على المشاركة، يرجى تسجيل اسمك أدناه
الباحث_______________________________  التاريخ ______/______/______  
 ____________________________  أسم المشارك
 
        ____________________________      التوقيع
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Project title: The development of a new anthropometric tool for assessing 
overweight and obesity in Saudi adult population.  
Purpose of the 
Study  
 
The purpose of this study is to examine whether neck 
circumference (NC) can be used to identify overweight, obesity, 
high lipid profile and their associated risk factors, as well as to 
establish NC gender-specific cut-off point values for Saudi 
population in the city of Riyadh. Your participation in this project 
will aid us to find standardized assessment tools to determine 
accurate prevalence, treatment protocols, and achieve control of 




After you have read and signed this consent and agreed to 
participate, you will be interviewed in an empty room within the 
same clinic to provide you comfort.  
Questionnaires: During this visit you will also be asked to 
complete a questionnaires that will ask you about yourself, your 
medical history and immediate family medical history, your level 
of physical activity, as well as a variety of dietary habit and 
practices.  
Physical Measures: prior to seeing your doctor and during the 
routine preparation session, well- trained clinic in charge nurse, 
of the same sex as you, will take some extra measurements 
other than height (cm), weight (kg), with estimated time of 5-10 
minutes in order to be completed. These include: neck 
circumference (cm), waist circumference (cm), and body fat (%). 
You should be wearing light clothes, bare head and feet.  
We will use DEXA to measure your whole body fat and your lean 
body mass (muscle). After completing the doctor visit, you will be 
asked to visit the radiology department within the same center. A 
well-trained technician will explain the procedure to you, and 
then you will lie flat on the DEXA table. X-rays from the machine 
will be introduced into your body. We will ask you to lie still for 
about 5-10 minutes while the DEXA machine scans over your 
body. This procedure is not painful, but there could be some 
minor discomfort from lying in the same position. This discomfort 
will be minimized by keeping the time involved in making the 
measurements as short as possible, and by allowing you a break 
if necessary. During the DEXA scanning, you will be exposed to 
a tiny amount of radioactivity. The amount of radioactivity is 
equivalent to the amount you are exposed to when you are 
Appendix 2B 
Obesity Assessment Study –  Informed Consent (English)       Page   / 4 
 
2 
outside for five hours. The level of exposure is associated with a 
minimally increased risk.  
The physician will inform you about the study measures, e.g., 
weight, height, BMI along with a chart of weight categories, blood 
pressure, waist circumference along with risk cut-offs, body fat 
percentage along with a chart of typical ranges  
Blood test results: I will obtain some recent laboratory results 
(within 1week) of your medical record; plasma glucose, insulin, 
HDL cholesterol, triglycerides, and blood pressure. If your 
medical record does not have required biochemical parameters, 
we will schedule you for another visit to the laboratory in the 
same clinic within one week.  
Second visit if needed: within one week to Baseline:  
You have to attend fasting for 10-12hrs. A well-trained technician 
will explain the procedure to you, and then you will be seated 
and blood will be drawn from a vein in your arm using a needle. 
Total blood volume required is 6mL (approximately half 
tablespoon). If you have poor quality vein you will be excluded to 




There are minimal risks involved with assessment of body 
composition. you may feel uncomfortable having your body 
measured and you can elect not to participate in this portion of 
the assessment if you experience discomfort. The 
anthropometric measurements will be taken prior to visiting the 
doctor and during the routine preparation session by clinic in 
charge nurse, of the same sex as each participant, to minimize 
risk of discomfort or embarrassment.  
The DEXA level of exposure is associated with a minimally 
increased risk. The total radiation dose is extremely low, 0.01 to 
0.04 mrem per scan, which is within the range of background 
radiation and considerably less than conventional X-rays. A 
chest X-ray, for example, delivers a radiation dose of 40 mrem. 
This procedure is not painful, but there could be some minor 
discomfort from lying in the same position. This discomfort will be 
minimized by keeping the time involved in making the 
measurements as short as possible, and by allowing you a break 
if necessary.  
The risks associated with blood drawing include fainting, 
dizziness or becoming light-headed. However, If you loose 
consciousness or feel dizzy during the procedure, it will be 
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discontinued. And you will be asked to place your head between 
your knees. You will then be asked to lie down (in a supine 
position). Besides, if you with poor quality vein you will be 
excluded to avoid any unnecessary pain. You may also 
experience slight pain during the drawing of blood samples, and 
in some cases the possibility of bruising after the sample has 
been taken, but this generally disappears in about one to two 
days. In rare cases, the site of the blood draw can be infected, 
causing arm pain and redness; however, in such case you will be 
advised to come to the clinic for immediate antibiotic treatment.  
Potential 
benefits 
Although there are no direct benefits; this research will contribute 
to the establishment of an accurate prevalence of obesity and 
cardio-metabolic risk factors and better treatment protocols. 
Moreover, it will be a part of future novel research in the 
development of standardized assessment tools for Saudi Arabia.  
Confidentiality Any potential loss of confidentiality will be minimized by storing 
data in a locked cabinet in a locked office and in a password-
protected computer.  
If we write a report or article about this research project, your 
identity will be protected to the maximum extent possible. Your 
information may be shared with representatives of the University 
of Maryland, College Park or governmental authorities if you or 





Your participation in this research is completely voluntary. You 
may choose not to take part at all. If you decide not to participate 
in this study or if you stop participating at any time, you will not 
be penalized or lose any benefits to which you otherwise qualify.  
If you decide to stop taking part in the study, if you have 
questions, concerns, or complaints, or if you need to report an 
injury related to the research, please contact the investigator, 
David Lei, PhD at: 0121 Skinner Bldg. University of Maryland, 
College Park, MD 20742, 301-405-2143 dlei@mail.umd.edu, or 
Co-Investigator Reem Albassam. 9524 Lagersfield Cir Vienna, 
VA 22181, 571-239-9940, reem.albassam@gmail.com  
! !
Appendix 2B 






If you have questions about your rights as a research participant or 
wish to report a research- related injury, please contact:  
University of Maryland College Park  
Institutional Review Board Office  
1204 Marie Mount ! 
College Park, Maryland, 20742 
E-mail: irb@umd.edu  
Telephone: 301-405-0678 
This research has been reviewed according to the University of 




Your signature indicates that you are at least 18 years of age; you have 
read this consent form or have had it read to you; your questions have 
been answered to your satisfaction and you voluntarily agree to 
participate in this research study. You will receive a copy of this signed 
consent form. 




PARTICIPANT NAME  
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 هـ     /   /    تاريخ المقابلة
 
 م     /   /    تاريخ المقابلة
 




  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل سبق وشاركت في دراسة بحثية -
 
 ال أعرف   (  )ال                                 (  )نعم                      ( )   
 
 :البيانات االجتماعية والديمغرافية 
 
  . . . . . . . . . . .  :الجنس -
 
  أنثى( )ذكر               ( )
 
  . . . . . . . . . . . .  :العمر -
 
    --------------------- 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :مستوى التعليم؟ -
 
  االبتدائية( )                  القراءة والكتابةأجيد ( )                        أمي( )   
              دراسات عليا( )جامعي                  ( )                                   الثانوية( )                  المتوسط( )   
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :الحالة االجتماعية؟ -
 
 منفصل ( )                            متزوج( )                        أعزب( )   
                                    أرمل( )                       مطلق( )   
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :عدد األطفال -
 
                  - ( )واحد                            ( )ال يوجد                      ( )   
 أطفال                أكثر من ( )                         - ( )   
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :الوظيفة  -
 
 معلم               ( )طالب                 ( )                               ( ربة منزل)عاطلين عن العمل ( )   
 ممرض             ( )طبيب                 ( )تجارة            /رجل أعمال( )أعمال مكتبية             ( )   
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .: أخرى( )   
 
   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :معدل دخل األسرة الشهري -
 
 رس                           0444 -رس  0(  )رس             0444 -رس  0( )رس                                             0أقل من ( )   
 رس             0444 -رس  0( )رس         0444 -رس  0( )رس                                    0444 -رس  0( )   
 ال أعرف( 4)رس                  0أكثر من ( )رس                                  40444 -رس  0( )   
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل تدخن -4
           (سيجارة>)أدخن بعض األحيان(  )                    (سيجارة>)ال ابداً ( )   




 :تاريخ العائلة الصحي/  البيانات الصحية 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل يعاني احد أفراد العائلة من السمنة -
 
 األب فقط               ( )األم فقط                         ( )ال يوجد                 (  )   
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :غير ذلك( )أخ أو أخت                       (  )األم واألب             ( )   
 
  . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . :هل يعاني احد أفراد العائلة من إحدى األمراض التالية -
 
 أمراض القلب               ( )السكري                         ( )ال يوجد                 (  )   
 ارتفاع ضغط الدم( )ارتفاع الكولسترول            (  )الجلطة                 ( )   
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 :الصحي كترمشتاريخ ال/  البيانات الصحية 
 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل سبق وشخصك الطبيب بإحدى األمراض التالية -
 
 ارتفاع ضغط الدم               ( )السمنة                         (  )ال                        ( )   
 السكري                        (  (                            )ارتفاع السكر)معرض للسكري( )   
 أمراض القلب              (  )                فقر الدم          ( )الربو                   (  )   
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . : أخرى( 4)   
             
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :هل تتناول عالج محدد الرتفاع الدهون الثالثية -
 
 ال أعرف               (  )ال            (  )نعم                ( )   
 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل تتناول عالج محدد الرتفاع الكولسترول -
 
 ال أعرف               (  )ال            (  )نعم                ( )   
 
 
  . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . :هل تتناول عالج الرتفاع الضغط سبق و وصفه لك الطبيب  -
 
 ال أعرف               (  )ال            (  )نعم                ( )   
 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل تتناول عالج الرتفاع السكر سبق و وصفه لك الطبيب -
 
 ال أعرف               (  )ال            (  )نعم                ( )
 :            إذا  كانت اإلجابة نعم 
                     .  . . . . . . . . . . . . . .(:كم مرة تتناوله)التكرار ( ب/)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .: اسم الدواء( أ/)   
 . .  . . . . . . . . .(: منذ متى وأنت تستخدمه)المدة ( د/). . . . . . . . . . . . . . . . . . . .  (: الكمية في كل مرة)الجرعة ( ج/)   
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :هل تتناول فيتامينات أو مكمالت غذائية  -
 
 ال أعرف               (  )ال            (  )نعم                ( )   
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  (:سبق و وصفة لك الطبيب)هل تتبع حمية غذائية لغرض طبي  -
 
 ال أعرف               (  )ال            (  )نعم                ( )   
 :            إذا  كانت اإلجابة نعم 




( أو ألم في الصدر0 والدوخة0 وضيق في التنفس)المفاصل / العضالت / هل تعاني من أي مشكلة صحية مرتبطة بالعظام  -4
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :يمكن أن تتعارض مع ممارسة الرياضة؟
 
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . نعم (  )ال                ( )   
 
 
 :للنساء فقط 
  . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :عمرك عند البلوغكم كان  -
 
       . . . . . . . . . . . . . . . . . . . . . . . .: حددي    
  . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (:الحيض)متى كانت أخر دورة شهرية لك  -
 (                   دورة غير منتظمة)شهر الماضي  خالل ال(  (          )دورة منتظمة)الشهر الماضي( )   
 شهر متواصل  متوقفة لمدة (  )   
, كريم, سواء كان على هيئة حبوب)األستروجين أو البروجسترون هل سبق و تناولتي عالج هرموني مثل  -
  . .. . . .  . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (:.أو إبر, لصاقات الجلد
 ال أعرف               (  )ال            (  )نعم                ( ) 
 :            إذا  كانت اإلجابة نعم  
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 :مصدر المعلومات الغذائية 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :ما هو مصدر معلوماتك الغذائية -
 
 
            االنترنت و وسائل التواصل االجتماعي            ( )          الراديو و التلفزيون ( )         الجرائد و المجالت  ( )العائلة             ( )                  األصدقاء( ) 
                                                 (ي/حدد). . . . . . . . . . . . . . . . . . .: أخرى( )أخصائية التغذية                                        ( )            المنشورات  ( ) 
 
 
 :العادات والممارسات الغذائية 
 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :المنتظمة التي تتناولها يومياكم عدد الوجبات  -
 
 غير منتظم ( )ثالثة                (  )اثنتين                            ( )واحدة                        ( )   
 
  . . . . . . . . . . . . . . . . . . . . . . .  :عادةً ( تتركها)ما هي الوجبة التي تهملها  ,إذا لم تكن ثالث وجبات -أ/ 
 
 العشاء               (  )الغداء                            (  )اإلفطار                ( )   
 
 
  . . . . . . . .  . . . . . . . . . . . . . .(األكثر استخداماً  نوعيةال -خيار واحد فقط). .  :عادًة طعامك اليومي يعتمد علي -
 
 (.اللحوم0 الدجاج0 األسماك0 البيض0 البقوليات0 والجبن)أطعمة غنية بالبروتين ( ) 
 (.الخبز0 المعكرونة0 األرز0 البطاطا)أطعمة عالية الكربوهيدرات ( ) 
 (.             السجق والبطاطس المقلية والكعك وكريم0 والزبد)أطعمة عالية الدهون ( ) 




  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :كم حبة من الفاكهة تتناول يومياً  -
 
 يوم كل(  )ليست يومياً          ( ) ال أكل الفاكهة              ( )   
 ة
  . . . . . . . . . . . . . . . . . .. . . . . . . . .  (طازج أو مطبوخ)هل تحرص أن تشتمل وجباتك اليومية علي الخضار  -
 
 دائماً               (  )أحيانا            (  )ال ابداً                ( )   
 
   . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  :باليوم/كم وجبة خفيفة تتناول -
 
 ال أتناول              ( )مرة واحدة         ( )مرتين        ( )ثالث مرات   ( )أربع مرات      ( )خمس مرات أو أكثر        ( )   
   
  . .  . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . :وجبتك الخفيفة عادًة تتكون من -4
 
 فاكهة         ( )مشروبات غازية     ( )مكسرات           ( (          )شبس)رقائق البطاطا( )كيك            ( )شكوالتة                     ( )   




  . . . .  . . . . . . . .(. . . . . . . . .الطريقة األكثر استخداماً  -خيار واحد فقط). . .  :ما المحليات التي تستخدمها عادة -
 
 سكر الفواكهة               ( )العسل                                (  )السكر األبيض                            ( )   
 (ي/حدد: . . . . . . . . . . . . . . . . . . . . . . . . . . . . .)أخرى( (                               )وغيرة, سبلندا, سويت ان لو)المحليات الصناعية( )   
 
  . . . . . . . . . . . . . . . . .  . . . . . . . (الطريقة األكثر استخداماً  -خيار واحد فقط). :هيعادًة  طريقة طبخك اليومي -
 
 التشويح بكمية زيت قليلة      (   )بالفرن وبدون إضافة دهون        (  )الشوي أو السلق                       ( )   
 (ي/حدد: . . . . . . . . . . . . . . . . . . . . . . . . . . . . .)أخرى( )ال اعرف                                 ( )التشويح بالزيت                         ( )   
 
 
  . . . . . . . . . . . . . . .. . . (الدهون األكثر استخداماً  -خيار واحد فقط). .  :نوع الدهون المستخدمة بالطبخ عادًة هي -
 
 سمن نباتي(   )زيوت النخيل                           (  )زيت الذرة  او تباع الشمس          ( )   
 (ي/حدد: . . . . . . . . . . . . . . . . . . . . . . . . . . . . .)أخرى( )ال اعرف                                  ( )سمن حيواني أو زبده                 ( )   
 
  . . . . . . . . . . . . . . .. . . (المنتج األكثر استخداماً  -خيار واحد فقط). . . . . .  :ماذا تتناول عادةً , من منتجات األلبان -
 
 خالي الدسم               (  )قليل الدسم                           (  )كامل الدسم                            ( )   
 
  . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :هل تتناول الوجبات السريعة -
 
 ال              (  )أحيانا                                     (  )نعم                                       ( )   
 
  . . . . . . . . . . . . . . . . . . . . . . . . .  :كم مرة تناولتها خالل األسبوعين الماضيين, إذا لم تكن اإلجابة ال -
 
 . . . . . .()عدد المرات   
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  . . . . . . . . . . . . . . . . . . . . (:عالء الدين, ماك, برجركنج, شاورمر)ما حجم الوجبة التي تتناولها عادًة  -
 




 :طريقة المعيشة و النشاط البدني 
 
. أو للمتعة, التنقل, البدنية هي أي نشاط  يزيد ضربات القلب عن المعدل الطبيعي0 سواء كان هذا الجهد ناتج عن العمل0 الحركةاألنشطة 
كمية الطاقة التي بالنشاط  (شدة)حدة  تبط ترو. ةً الذي تقوم به عادالنشاط البدني  (شدة)حدة عن كمية و أسئلةالتالية  فقرةال
 .ألنشطةا تلكتستخدمها للقيام ب
 
 
  . . . .  . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :ةً هل تمارس الرياضة عاد -
 
                (طوال السنة)نعم علي مدى العام ( )في بعض المواسم                   (  )                       أحيانا(  )                   ال( )   
 
 93انتقل إلى سؤال   اإلجابة الإذا كانت 
 
A- هاما نوع الرياضة التي تمارس: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . .  
 
 ايروبك               ( )السباحة         (  )         الجري(  )المشي                ( )   
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .: أخرى( )   
 
B- كم مرة باألسبوع تقوم  بممارسة الرياضة:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 كل يوم             ( )       ست  ( )       خمس ( )     اربع ( )      ثالث ( )       مرتين   (  )مرة           (  )ليس كل أسبوع     ( )   
 (ي/حدد). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . : أخرى( 4)   
C- كم مدة التمرين في كل مرة:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
                   ارتفاع نبضات القلب أوحتى التعرق  ()                  ( . . . . . . . . . . . . . . . . . . . . . . . .)دة الم( )   
 
 
  . . . .  . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . ( خيار واحد فقط).  :نمط حياتك المعيشي يعتبر -
 
 (                   تسوق, أعمال منزلية)قليل الحركة ( ) (   أو الطباعة, القراءة, مشاهدة التلفزيون) عديم الحركة  ( )   
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 الرسمي فقط مالجزء لالستخدا اذه









     Anthropometrical data: 
  HEIGHT (Ht)  =    ---------- Cm 
 
  WEIGHT (Wt)=    ---------- Kg 
 
   Neck circumference  =     --------- Cm 
 
  Waist circumference =     --------- Cm 
 
   Body Mass Index (BMI) =  ---------Kg/M  
 
  Body fat %  =                  ---------% 
 
 Laboratory Results:  
 Cholesterol            -----------   Systolic BP         -----------   
 
 Triglycerides (TG)     ----------   Diastolic BP        -----------  
 
 High-density lipoprotein (HDL)      ----------   Fasting glucose    -----------    
 
 Low-density lipoprotein (LDL)       ----------   Fasting Insulin     -----------  
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 3 4 1   /     /                               Date of the interview  
 
 1 0 2   /     /                               Date of the interview 
 
 
                           Center:  ______________________  
 
                           Serial number: ___________  
 
                           Lab code: _______________  
 
1- Have you participated in any research studies before?:  . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . .  
(1) Yes                   (2) No               (3) I don’t know  
 
   Socio-demographic Data: 
 
    __________ 
 
        (1) Male              (2) Female  
 
 4- Education level:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
(1) Illiterate    (2) read and write     (3) Elementary 
(4) Intermediate            (5) Secondary                      (6) Graduate    (7) Post- graduate[code=8] 
 
   5- Marital Status:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
(1) Unmarried               (2) Married (3) separated  
(4) Divorced    (5) Widowed 
   6- Number of children:   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
(1) None     (2) One    (3) 2-3    
(4) 4-6   (5) More than 6 
   7- Occupation:   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 (1) Unemployed (Housewife)      (2) Student (3) Teacher        
(4) Office work (5) Business       (6) Medical Doctor         (7) Nurse    
(8) Retired                    (9) Millenarian                  (10) Other _____________________  (specify)  
 
   8- Average Monthly Family Income:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 (1) Less than 1,999                               (2) 2,000 SR - 4,999 SR                  (3) 5,000 SR - 7.999 SR      
(4) 8.000 SR -10.999 SR                       (5) 11,000 SR - 13.999 SR              (6) 14.000 SR -16.999 SR 
(7) 17,000 SR - 19.999 SR                    (8) More than 20.000 SR                 (9) Un known  
   9- Your smoking status (cigar, pipe, shisha [water pipe or flavored tobacco]) is:   . . . . . . . . . . . .  
(1) Never smoke                          (2) Current some day smoker       
(3) Former smoker                       (4) Current every day smoker   
 
 Family Medical History / Health History Data:  
 
   10- Family history of obesity:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
(1) None             (2) Mother only                   (3) Father only]     
   (4) Mother and Father                (5) Sister or Brother            (6) Other____________  (specify) 
 
   11- Any family history of the following  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 (1) None (2) Diabetes     (3) Heart diseases     
(4) Stroke                     (5) High cholesterol (6) High blood pressure/ Hypertension   
(7) Cancer                    (8) Osteoporosis               (9)Other_____________________________  
(specify) 
  
   2-  Age: 
 3-  Gender: 
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  Subject’s Medical History Data:  
 
   12- Have you ever been diagnosed with any of the following?. . . . . . . . . . . . . . . . . . . . . . . . . 
 
(1) None          (2) Obesity  (3) High blood pressure (Hypertension) 
(4) Pre-diabetes (elevated blood sugar)                  (5) Diabetes                  (6) Asthma                    
(7) Anemia                       (8) Heart diseases         (9) Other_________________________ (specify) 
 
   13- Are you taking specific treatment for hypertriglyceridemia?  . . . . . . . . . . . . . . . . . . . . . . . .  
 
(1) Yes (2) No (3) Don’t know  
 
   14- Are you taking treatment for previously diagnosed hypercholesterolemia?. . . . . . . . . . . . . . . 
 
(1) Yes (2) No (3) Don’t know  
 
   15- Are you taking treatment for previously diagnosed hypertension?. . . .. . . . . . . . . . . . . . . . . 
 
(1) Yes (2) No (3) Don’t know  
 
   16- Are you taking treatment for previously diagnosed diabetes?. . . .. .. .. . . . . . . . . . . . . . . . . 
 
 (1) Yes (2) No (3) Don’t know  
 If yes:  
(2/A) Name: _____________________ (2/B) Frequency (how often take): ________________ 
(2/C) Dose (how much take): _____________ (2/D) Duration (how long been taking): ____________ 
 
 
   17- Are you taking any vitamins or dietary supplements?  . . . . . . . . . . . . .. . . . .. . . . . . . . . . .  
 
(1) Yes (2) No (3) Don’t know 
 
   18- Are you following any special diet for medical purposes? ... . . . .. . . . . . . . . . . . . . . . . . . . .  
 
(1) Yes              (2) No                  (3) Don’t know  
 
   
19- Any orthopedic/muscular/joint/medical conditions (eg. chest pain, dizziness, shortness of breath 
that would interfere with exercise training?.. . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . 
 
 (1) No (2) Yes:  ____________________________ (specify) 
 
   
  For females only,  




   21- When was your last menstrual cycle?  . . . . . . . . . . . .. .  . . . . . . . .. . . . .. . .. . . . . . . . . .
 
(1) Last month (regular mensuration)                  
(2) Within the past 12 months (irregular mensuration)  
(3) Stopped for at least 12 consecutive months 
 
   
22- Have you ever used female hormones such as estrogen and progesterone? Please include any 
forms, such as pills, cream, patch, and injections.. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
(1) No                (2) Yes               (3) Don’t know 
If yes:    
(2/A) Purpose (why take): ______________________ (2/B) Duration (how long been 
following):_______________  
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  Nutrition knowledge:  
 
   23- What is the source of your nutritional information? . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
 (1) Friends          (2) Family (3) Newspaper &Magazine   (4) Radio & TV               
(5) Internet & social media (6) Booklets   
(7) Dietitian            (8) Other__________________________ (specify) 
 
 
  Dietary habit and practices:  
 
   24- How many regular main meals do you eat daily?  . . .. . . . . . . . . .. . . . . . . . . . . . . . . . . .  
 
 (1) One (2) Two           (3) Three   
(4) Irregular             
   IF not three, which meal do you skip?  . . . . . . . . . . . . . . ... . . .. . . .. . . . .. . . . . . . . .  
 
(1) Breakfast   (2) Lunch                             (3) Dinner   
 
   25- Your diet is based mainly on: . .. . . . . . . . .. . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . . . .
 
(1) High protein content food (meat, chicken, fish, egg, legumes, and cheese).   
(2) High carbohydrate content food (bread, pasta, rice, potato).   
(3) High fat content food (sausage, fried potato, cakes, cream, butter).  
(4) Different food every day. 
 
   26- Do you concern to eat fruit daily? . .. . . . .. . . . . . . . . . . . . . . . . .  . . . . . . .. . .. . . . .. . .  
 
 (1) Don’t eat           (2) Not every day                 (3) Every day  
 
   Daily fruit consumption: .. . . . .. . . . . . . . . . . . . . . . .. . . .. . . .. . . . . . . . . . . . . . . . . . 
I eat ( ________ ) pieces 
 
   
27- Do you concern to eat two serving of vegetables daily (Do you ensure that your meals contain 
vegetables daily)? . .. . . . . . . . . .. . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
 (1) Never          (2) Sometimes  (3) Always   
 
   28- How many snack do you eat /day? . . . . . . .. . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . . . 
 
(1) 5 times or more (2) 4 times (3) 3 times (4) Twice (5) once  
(6) never  
 
   29- Your snacks are based mainly on: . . . . .  . .. . . . . . .. . .. . . . .. . . . .. . . . .. . . . . . . . . . . .
 
(1) Chocolate  (2) Cake                (3) Chips         (4) Nuts     
(5) Regular soft drink                                        (6) Canned juices              
(7) Other _____________________  (specify) 
 
   30- What sweeteners do you use usually? . .. . . .. .. . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . .
 
(1) Don't use          (2) Regular sugar                  (3) Honey                    (4) Fruit sugar      (5) Artificial 
sweeteners                
(6) Other ______________  (specify) 
 
   31- The way that you usually cook with: . .. . . .. .. . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . . 
 
(1) Grilled, boiled    (2) Cooks in the oven with out fat                              (3) Cooks in a pan with little fat  
(4) Cooks in a pan with fat                                 (5) Frying                      (6) Don’t know 
 
   32- Cooking fat that you use usually? . . .. . . . .. . . . .. . . . . . . . . . . . . . . .  . .. . ... .. .. .. . .. .
 
(1) Don’t use         (2) Corn oil, sunflower            (3) Palm oil                   (4) Margarine 
(5) Butter                 (6) Don’t know                      (7) Olive oil 
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   33- From dairy products, what do you consume usually?.. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . 
 
(1) Don’t use        (2) Regular                            (3) Low fat         (4) Skimmed 
 
   34- Do you eat fast foods?  . . . .. . . . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . . . .. . . . .. . .. ..  
 
(1) Yes                (2) Sometimes                        (3) NO 
 
   35- If yes, how many times during the last 2 weeks: . . .. . . . .. . .. .. . . . . . .. . . . . . . . . . . . . .
 
( ________ ) times 
 
   36- What is your meal size usually? (Aladdin, Burger king, Shawarmer, Mc Donald’s). . . . . . . . . . .
 
 (1) Small             (2) Medium                             (3) Large                        (4) Super size                                     
(5) Other ______________(specify)  
    
 
  Physical activity and life style:  
 
Physical Activities are any activities that increase your heart rate above its resting rate, whether you 
do them for work, transportation, or pleasure. The following questions ask about the amount and 
intensity of physical activity you usually do. The intensity of the activity is related to the amount of 
energy you use to do these activities. 
 
   37- Do you usually practice a physical activity? . . .. . . . .. . . . .. . . . .. . . . .. . . . . . . . . . . . . . 
 
(1) Never (2) Some times (3) In some seasons      
(4) Always during the entire year  
  
   37-A- What type of physical activity you do practice?.. . . . .. . . . .. . . . .. . . . . . . . . . . . . . 
 
(1) Walking  (2) Running   (3) Swimming   
(3) Aerobics (5) Other ___________________ (specify) 
  
   37-B- How many times do you exercise/week?.. . .. . . . . . . .. . . . .. . . . .. . . . . . . . . . . . . 
 
(1)1 or less  (2)  (3)  (4)  (5)  (6)  (Daily)      
 
   37-C- For how long do you exercise each time? . .. . . . . . . .. . . . .. . . . .. . . . . . . . . . . . . 
 
(1) ( _________ )minute  Or        (2) Till sweating or heart beat raises 
 
   38- Your lifestyles is:   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .  . . . . .
 
 (1) Very Sedentary (typing, reading, and watching TV) (2) Sedentary (cleaning, shopping)   
(3) Moderate active (hard job)                                               (4) Very active ( swimming, cycling)  
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   Anthropometrical data: 
 
                  HEIGHT (Ht)  =    ---------- Cm 
 
  WEIGHT (Wt)=    ---------- Kg 
 
  Body Mass Index (BMI) =  ---------Kg/M² 
 
   Neck circumference  =     --------- Cm 
 
  Waist circumference =     --------- Cm 
 
  Body fat %  =                  ---------% 
 
  Laboratory Results:  
 
 Cholesterol     -----------   Systolic BP          -----------   
 
 Triglycerides (TG)     -----------   Diastolic BP         -----------  
 
 High-density lipoprotein (HDL)     ----------   Fasting glucose    -----------    
 






  Do you concern to eat fruit daily?   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  




 Do you concern to eat two serving of vegetables daily (Do you ensure that your meals contain vegetables 
daily)? 
(1) Never[code=1]                   (2) Sometimes[code=2]                  (3) Always[code=3]              
 
 
  What sweeteners do you use usually?   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
(0) Don't use [code=3]                   (1) Regular sugar [code=1]                 (2) Honey [code=2] 
(3) Fruit sugar [code=2]                 (4) Artificial sweeteners [code=3]         (5) Other [code= decide 
later], in our sample, no one responded “Other” 
 
 
  The way that you usually cook with:   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
(1) Grilled, boiled [code=3]                        (2) Cooks in the oven with out fats [code=3]  
(3) Cooks in a pan with little fat [code=2]    (4) Cooks in a pan with fat [code=1]            
(5) Frying [code=1]  
(6) Don’t know [code= decide later] in our sample, no one responded “don’t know”                        
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Appendix 5 
Measures of additive interaction 
Since we are interested in the joint exposure effects of 2 factors (large neck and 
large waist; large neck and high BMI) on disease risk, I calculated the additive 
interaction. For the calculations of the measures of additive interaction between two 
dichotomous risk factors, we have four possible combinations and, thus, four exposure 
categories.  As suggested by Rothman et al, and Andersson et al. (193, 194), I computed 
new composite variables, indicating a variable of joint exposure to both risk factors (11), 
a variable of exposure to one of the risk factors only (10 or 01), and the joint reference 
variable of no exposure (00).  
Syntax 
IF (Neck cutoff= 2 and Other measure= 2) ind11 = 1 .  
EXECUTE. 
IF ((Neck cutoff = 2 and Other measure = 1) or  
(Neck cutoff = 1 and Other measure = 2) or  
(Neck cutoff = 1 and Other measure = 1)) ind11 = 0. 
EXECUTE.  
IF (Neck cutoff = 2 and Other measure = 1) ind10 = 1.  
EXECUTE.  
IF ((Neck cutoff = 2 and Other measure = 2) or  
(Neck cutoff = 1 and Other measure = 2) or  
(Neck cutoff = 1 and Other measure = 1)) ind10 = 0. 
EXECUTE.  
IF (Neck cutoff = 1 and Other measure = 2) ind01 = 1.  
EXECUTE.  
IF ((Neck cutoff = 2 and Other measure = 2) or  
(Neck cutoff = 2 and Other measure = 1) or  
(Neck cutoff = 1 and Other measure = 1))ind01 = 0. 
EXECUTE. 
 
Logistic regression analysis is then used to estimate the ORs using these new 
indicator variables. As for logistic regression, in cross-sectional study, we make the 
Appendix 5 
common assumption that the odds ratio can be used instead of the relative risk. The 
model includes terms for three of the four possible combinations of exposure while the 
fourth category used as reference category (195). 
Three different measures exist to quantify the amount of interaction on an additive scale 
(193):  
1) The Relative excess risk due to interaction (RERI), which can be interpreted as the 
risk that is additional to the risk that is expected on the basis of the addition of the 
ORs under exposure, calculated as the difference between the expected risk and the 
observed risk: RERI=OR11 –OR10 –OR01 +1  
2) The Attributable proportion due to interaction (AP), which is interpreted as the 
proportion of disease or mortality that is due to interaction among persons with both
exposures: AP = RERI/OR11  
3) The Synergy index (S), which can be interpreted as the excess risk from exposure to 
both exposures when there is interaction relative to the risk from exposure without 
interaction: S = [OR11 – 1]/[(OR10 – 1) + (OR01 – 1)]  
  
Appendix 5 
The steps of the CI 95% calculation: 
If we let  ℎ(0!), ℎ(0!), and ℎ(0!) denote the estimated coefficients for OR10, OR01, and 
OR11, respectively. 
To find the variance of ℎ(0), I used the standard delta method based on a Taylor Series 
expansion of h about 0 , whereby the variance estimate is of the general form:  
!"# ! 0 = !!!!!! + !!!!!! + !!!!!! + !"#"!!!" + !"#"$!!" + !!"!"#!!" 
To find ! in SPSS, I used the covariance matrix syntax: 
   REGRESSION 
  /DESCRIPTIVES MEAN STDDEV CORR SIG N COV 
  /MISSING LISTWISE 
  /CRITERIA=PIN(.05) POUT(.10) 
  /NOORIGIN  
  /DEPENDENT Metabolic Syndrome 
  /METHOD=ENTER AGE ind11 ind10 ind01 
 
As per Hosmer and Lemeshow (195) I used the following denotations 
! In calculation CI 95% for RERI  
h1= -10 coefficient 
h2= -01 coefficient  
h3=  11 coefficient  
 
! In calculation CI 95% for AP 
h1= 10coefficient  ÷ 11coefficient 
h2= 01coefficient  ÷ 11coefficient 
h3= (10coefficient + 01coefficient − 1) ÷11coefficient 
 
! In calculation CI 95% for S 
h1= -10coefficient ÷ (10coefficient + 01coefficient −2)  
h2= -01coefficient ÷ (10coefficient + 01coefficient −2)  
h3= -11coefficient ÷ (11coefficient −1)  
 
In the absence of an interaction effect, RERI and AP equal 0 and S equals 1 (193, 194, 
195, 1). 
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